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Rats were given drugs, many of which affect 5-hydroxytryptamine
(5HT) metabolism in brain. Interference microscopy was used to measure
the nucleolar dry mass of isolated nuclei from various interneurones. In
all experiments the nucleolar dry mass of the median raphe neurones in the
brainstem was measured: these neurones synthesize 5HT. The isolated
nuclei of various hypothalamic neurones were also examined: the nucleolar
dry mass of the suprachiasmatic neurones (which are postsynaptic for 5HT-
containing terminals) and of the arcuate neurones was measured in most
experiments. In a few experiments, the nucleolar dry mass of ventromedial,
dorsomedial, preoptic and posterior neurones was also measured.
Following the daily administration of the monoamine-depleting drug,
reserpine, the nucleolar dry mass of raphe neurones increased significantly
from day 5 onwards, to an extent dependent on the dosage. Four days after
withdrawing the drug, the dry mass value was again normal. The nucleolar
dry mass of the suprachiasmatic neurones increased in one experiment, but
not in another when larger doses of reserpine were used. The nucleolar
dry mass of other hypothalamic neurones (apart from the ventromedial
neurones) was not affected by reserpine. The drug oxypertine, which
depletes only noradrenaline in brain, was given daily for 8 days; the
nucleolar dry mass of raphe neurones did not change.
The daily administration of monoamine oxidase inhibitors alone for
up to 10 days, or together with reserpine for 7 days, did not alter the
nucleolar dry mass of the neurones studied. The stresses of dehydration
for 5 days or the daily injection of aqueous and oily solutions for 9 days did
not affect the nucleolar dry mass of the raphe neurones*
Tricyclic antidepressant drugs (which inhibit the uptake of 5HT by
neurones) were given daily for up to 9 days. The nucleolar dry mass of
raphe and supraehiasmatic neurones decreased. For raphe neurones, the
larger the drug dosage and the more potent the drug, the less pronounced
was the decrease in dxy mass. With suprachiasmatic neurones the higher
drug dosages were the more effective.
The administration of lithium, which accelerates the uptake of 5HT
by neurones, increased the nucleolar dry mass of raphe neurones, but not
of suprachiasmatic and arcuate neurones.
Various monoamines, their precursors and their analogues were given
by intraventricular infusion or by intraperitoneal injection for 7 days or more.
The nucleolar dry mass of raphe neurones decreased only after 5HT, melatonin
and tryptophan.
When diamorphine was given daily, the nucleolar dry mass of raphe and
suprachiasmatic neurones was maximal at days 11-12 and days 15-18 respec¬
tively. The nucleolar dry mass of other neurones did not change.
In rats receiving barbitone orally for up to 37 days, the nucleolar dry
mass of raphe, arcuate and suprachiasmatic neurones was unchanged at
day 5; but a significant decrement was seen by day 14. This nucleolar change
was most pronounced in the raphe neurones (where it was maintained for 37 days)
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and least pronounced in the suprachiasmatic neurones. Six days after
withdrawing barbitone, the nucleolar dry mass of these neurones reverted
to normal.
The effect on neuronal nucleolar dry mass of altering the levels of
various steroid hormones was investigated. With daily injections of
testosterone for 6-14 days, the nucleolar dry mass of raphe neurones
increased, while that of suprachiasmatic neurones decreased. The injec¬
tion of cortisone for 14 days had no effect on the raphe neuronal parameter.
After adrenalectomy, alone or combined with cortisone injections, no
nucleolar changes were seen in the raphe, arcuate or suprachiasmatic
neurones.
The changes in the nucleolar dry mass of various neurones were
discussed in relation to the altered metabolism of brain 5HT reported to
follow these experimental procedures.
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"I have often admired your consummate wisdom, O Cato. It
is shown in many ways, but in none more perfectly than in the singular
ease and cheerfulness with which you bear the weight of years" (Cicero:
'De Senectute'). Thus I pay tribute to the brio and sagacity of my
youthful, octogenarian father. While this thesis was being prepared,
this Celtic Cato frequently gave enthusiastic encouragement and supported
morale. He also lent that calming sense of perspective which was celebrated
by the scientist, Omar, son of Ibrahim the Tentmaker:
The Wordly Hopes men set their Hearts upon
Turns Ashes - or it prospers; and anon,
Like Snow upon the Desert's dusty Face
Lighting a little Hour or two - is gone.
How long, how long, in infinite Pursuit
Of this and That endeavour and dispute?
Better be merry with the fruitful Grape
Than sadden after none, or bitter, Fruit.
But leave the wise to wrangle, and with me
The Quarrel of the Universe let be:
And, in some corner of the Hubbub coucht,
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1.1 The metabolic role of neuronal nucleoli
The nucleolus is essential for the synthesis and assembly of cellular
ribosomes (1-3). For example, anucleolar mutants of Xenopus cannot
synthesize ribosomal ribonucleic acid (4); they lack the ribonucleoprotein
granules which are components of normal nucleoli (5) and which, it is thought,
are the precursors of ribosomes (6). Using both autoradiographic and sedimen¬
tation techniques, the incorporation of 3H-cytidine into ribonucleic acid by
fibroblasts has been studied in the presence and absence of actinomycin D:
ribosomal ribonucleic acid was found to originate from nucleolar ribonucleic
acid (7). This finding has been supported by the results of studies on nucleic
acid hybridization (8), and also by the demonstration by microchemical methods
that the base compositions of both nucleolar and ribosomal ribonucleic acid are
similar (9).
In neurones, nucleolar changes accompany prolonged alterations of
cellular synthetic activity. For example, nucleolar volume is correlated with
the cytoplasmic content of ribonucleic acid (10), which in turn is linked to the
rate of protein synthesis in the neurone (11). During the sustained osmotic
stimulation which accompanies salt loading, the volume and ribonucleic acid
content of nucleoli in supraoptic neurones increase (12). The relationship
between nucleolar changes and the rates of ribosome and protein synthesis
in various neurones has been confirmed in other studies (13-15).
Techniques of ultraviolet absorption microspectrography and inter¬
ference microscopy have been used to monitor changes in the nucleic acid
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content and dry mass respectively of neuronal nucleoli (16, 17). In the
response of hypoglossal neurones to injury, the nucleic acid content of
these neurones' nucleoli rises initially, to be followed by a similar change
in their cell bodies (18). During dehydration, the supraoptic neurones of
rats yield increasing values for nucleolar nucleic acid and dry mass, and
also for cell body nucleic acid (19, 20). In lactating rats, a similar quanti¬
tative relationship has been demonstrated between nucleolar nucleic acid and
dry mass of the paraventricular neurones and the functional demand for
hormone production by these neurones (21, 22).
The hypoglossal, supraoptic and paraventricular cells have distinctive
motoneurone or neurosecretory functions. The aim of the present investi¬
gation was to detect changes in the nucleolar dry mass of various interneurones
in the brainstem and hypothalamus.
1.2 The raphe neurones
1.2.1 Introduction
The raphe nuclei are situated in the brainstem of the central nervous
lystem; many neurones in these nuclei contain 5-hydroxytryptamine (5HT)
(23, 24). By using techniques such as histofluorescence (25, 26), biochemical
analysis and lesion-induced degeneration, axons from the 5HT-containing
raphe neurones have been demonstrated in tracts which terminate in various
regions of the central nervous system, - particularly in the forebrain, hypo¬
thalamus, and spinal cord (27-36).
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1.2.2 The biochemistry of 5HT in raphe neurones
The ">HT within the raphe neurones is synthesized there. The
principal and other suggested pathways for brain 5HT metabolism are
summarised in Fig. 1.2.2.
1.2.3 5HT synthesis in raphe neurones
Tryptophan is actively transported (63) across the membrane of all
parts of raphe neurones (64); the Isolated neuronal terminals retain the
capacity for accumulating tryptophan (65, 66). The speed of this process and
the resulting concentration of tryptophan in raphe neurones may influence
their rate of 5HT synthesis, since the rate-limiting enzymic step for increases
in 5HT production is the hydroxylation of tryptophan (67-74). However there is
much evidence to support the view that major changes in the rate of 5HT
synthesis depend on the availability of tryptophan hydroxylase, rather than of
its substrate. For example, the saturation of tryptophan hydroxylase by
tryptophan in brain tissue is almost complete (75-77). Excess tryptophan
can inhibit tryptophan hydroxylase, at least in vitro (77). When more trypto¬
phan is made available in brain tissue, there is not a consistently parallel
increase in the concentration ox turnover of 5HT (78-81). In regions of the
adult or developing brain, 5HT concentration correlates well with tryptophan
hydroxylase activity (82-84) but not with the concentration of tryptophan (85).
Lastly, when tryptophan hydroxylase is inhibited, its declining activity runs
parallel to the fall in 5HT concentration (37).
Tryptophan hydroxylase is specific (86-88). In brain, its presence
exclusively in the raphe neurones ensures that only in these neurones is 5HT
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produced from tryptophan (89). Tryptophan hydroxylase is synthesized
mainly in the cell bodies of the raphe neurones, and is then transported
distally to their terminals (38, 90-92). However the synthesis of some
enzyme within the terminals themselves cannot be excluded in view of the
evidence that ribonucleoprotein is present in neuronal axons and terminals
(93-98) and that protein synthesis takes place there (99-106). Far example,
the production of the biosynthetic enzymes for noradrenaline in noradrenergic
terminals may be controlled by "informational molecules" synthesized in the
cell bodies of the neurones, and subsequently transported to the terminals
(107-108).
Although the enzyme aromatic-L-amino-acid transferase (AAAT),
like tryptophan hydroxylase, is probably synthesized in the cell bodies of
the raphe neurones and then transported to their terminals (109, 110), AAAT
differs from tryptophan hydroxylase in significant respects. In brain tissues
other than the pineal gland, AAAT is not saturated (78, 86, 111). AAAT is
also non-specific (112-115), closely-related enzymes being present in other
monoaminergic neurones (116) as well as in neuroglia and capillary
endothelium (113).
Whereas 5HT-synthesizing enzymes are formed mainly in the cell
bodies of the raphe neurones, there is evidence that 5HT itself is produced
mostly within the terminals of these neurones. For example 5HT is
synthesized autonomously by the terminals in brain slices (117) and synapto-
somes (118); adult values for 5HT concentration in the maturing brain are
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approached only as the nerve endings develop (119); in the circadian
rhythm described for brain 5 HT concentration (120-123), the amplitude of
change is maximal in regions rich in 5HT-containing terminals, but minimal
in those regions containing the raphe neuronal cell bodies (124). Neverthe¬
less, some of the 5HT in raphe neuronal terminals may be synthesized in
their cell bodies and then conveyed along their axons to the terminals.
Various findings support this contention. Firstly, when the molluscan brain
is perfused with solution containing tritiated tryptophan or 5-hydroxytryptophan
(5HTF), the isotope label is detectable over the cell bodies of the 5HT-
containing neurones, - and in particular over the Qolgi apparatus -, whereas
little or no label is found over the terminals (123). Secondly, when monoamine
oxidase (MAO) in mammalian brain is inhibited, 3HT fluorescence is seen
forming firstly as a perinuclear ring in the raphe neurones and then permea¬
ting their ceil body cytoplasm before eventually spreading to their axons and
terminals (126); in noradrenaline-containing neurones a similar sequence
has been demonstrated after MAO inhibition, and also for the return of
noradrenaline histofluorescence after reserpine (126-128). Thirdly, small
amounts of 5HT accumulate above constricted or damaged segments of the
5HT-containing axons in molluscan and mammalian central nervous systems
(129, 130), in a manner resembling the accumulation of noradrenaline in
ligated axons of sympathetic neurones (131-134).
1.2.4 5HT breakdown in raphe neurones
The breakdown of 5HT into 5-hydroxy-indole acetic acid (5HIAA) is
catalyzed by MAO (135-137), a family of relatively nonspecific enzymes
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<138-145). MAO plays an important role in regulating the amount of
"free" 5HT in the cytoplasm of raphe neurones (146, 147).
The cellular site of MAO synthesis in raphe neurones is unclear.
However the inference of work on other monoaminergic neurones is that
neuronal MAO is synthesized tn the cell bodies (148, 149) and terminals
(103) of neurones, but possibly also in adjacent non-neural cells (149, 150).
Indeed, MAO-contalning cells which are post-synaptic to monoaminergic
neurones, or which have no apparent synaptic communication with them,
may be partly responsible for inactivating the monoamines released from
those neurones (145, 151-155).
1.2.5 5HT storage in raphe neurones
Many vesicles of diameter ranging from 50nm to 170nm are present
at the raphe neuronal terminals close to the synaptic clefts (156, 157). In
various monoamine-containing cells, comparable organelles act as monoamine
stores (158-164); this is also their function in raphe neuronal terminals (165,
166). Indeed, most of the 5HT in raphe neurones is bound within these
vesicles (126, 167-171) which afford protection from cytoplasmic MAO (172-
175). When the 5HT content of raphe neurones is suddenly increased, either
by tryptophan-loading (61, 139, 176) or by the administration of 5HT (137,
177), the intraneuronal concentration of 5HT rises only initially; the con¬
currently-elevated concentration of 5HIAA results from free cy toplasmic
5HT being degraded by MAO, once the vesicular stores for 5HT have been
filled. When these vesicles are disrupted by reserpine, the concentration
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of 5HT in brain falls precipitously, while that of 5HIAA increases.
Because of their anatomical and biochemical complexity, it was
long assumed that the vesicles in monoaminerglc terminals are transported
there from their blosynthetic sites in the neuronal cell bodies (178, 179).
This view has been sustained by subsequent findings. For example,
vesicles are reported in the perinuclear zone of raphe neurones, often
close to the Gqlgi apparatus (24, 74, 180). In other neurones, this cellular
region is also implicated in the synthesis of vesicles (181,182); for instance,
workers have demonstrated the reserpine-sensitivity of the perinuclear ring
of noradrenaline fluorescence, which is seen in noradrenergic neurones
after reserpinization (126) (see Introduction 1.2.3).
The subsequent transport of vesicles to neuronal terminals has been
shown clearly in noradrenergic neurones and in 5HT-containing snail
neurones: after axonal ligation (129, 179), electrocoagulation (35), or
colchicine application (183), vesicles accumulate proximal to the affected
axonal segments. After the disruption of the vesicles in noradrenergic
terminals by reserpine (184), recovery of function in these terminals
depends on the arrival by axonal transport of vesicles synthesized in the
cell bodies (29, 185-189).
Therefore, from both direct and indirect evidence, it appears that
the synthesis of the storage vesicles of raphe neurones is a metabolic
function of their cell bodies.
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1.2.8 The release and recapture of 5HT by raphe neurones
There is considerable evidence that raphe neurones release 5HT from
their terminals: (a) endogenous and exogenous 5HT is released from brain
slices when these tissues are stimulated electrically or by exposure to a
high-potassium medium; the release of tritlated water and 14C-urea is
unchanged under these circumstances (190-192); (b) small amounts of 5HT
are released continuously into cerebrospinal fluid from brain tissue under
basal conditions: when the cell bodies of the raphe neurones are stimulated,
more 5HT is released (193-195), and the concentration of 5HIAA in brain
and cerebrospinal fluid rises (198-199); (c) in the distal segment of a
transected spinal cord, the failure of impulse transmission is associated
with the conservation of 5HT and the decline of 5HIAA formation (200).
When noradrenergic neurones are stimulated, only the vesicular nor¬
adrenaline is released from their terminals. As yet there is no direct
evidence that vesicular 5HT is of similar importance for the function of
raphe neuronal terminals (201).
Extraneuronal 5HT, whether of endogenous or exogenous origin, is
actively accumulated by the raphe neurones. The activity of the membrane
pump responsible for this function has been demonstrated in raphe and other
neuronal terminals by autoradiography (177, 202-208), electron microscopy
(125) and histofluorescence (209). But the evidence for a comparable uptake
efficiency in the cell bodies of 5HT-containing neurones is conflicting (125,
165, 209-211).
The re-uptake of released 5HT by the raphe neuronal terminals has
two consequences. Firstly, the partial replenishment of the presynaptic
SHT stores by this mechanism may minimize the need for 5HT synthesis
during neuronal activity: in sympathetic neurones, for example, 50-95%
of the noradrenaline released from the terminals is recoverable by membrane
transport (147, 212). Secondly, the actions of the released SHT on the post¬
synaptic cell membrane are terminated (see Discussion 3.3.4.3).
1.2.7 The effects of 5HT on the membranes of postsynaptic cells
The iontophoretic administration of 5HT provokes excitation or
depression of cerebellar (213) and cortical neurones (214-216); with
brainstem neurones, excitation, inhibition or mixed responses have been
elicited (217-219); with spinal motoneurones, 5HT is purely inhibitory (220).
In the suprachiasmatic nucleus, which contains large numbers of raphe
neuronal terminals (29, 32, 156, 210, 213, 221-223), neuronal firing is
inhibited by iontophoretically-applied SHT and by the electrical stimulation
of the raphe neurone bodies in the midbrain (213).
However there is evidence that tachyphylaxis occurs for 5HT in
peripheral tissues (153, 224-22C) and *130 in tb? 5H'T' synapses of the
molluscan (227) and mammalian (216, 219, 226, 229) central nervous system.
1.2.8 Measurement of brain SHT turnover
Raphe neuronal 5HT is the major source of the SHT in brain (23, 29,
230, 231). Therefore if SHT turnover in brain is measured, a major aspect
of raphe neuronal metabolism can be monitored (155).
The methods by which brain 5HT turnover is measured fall into two
categories (155, 232). In the first category comes the use of various
specific metabolic inhibitors. For example, 5HT turnover can be measured
indirectly, (a) from the initial rate of increase in brain 5HIAA concentration
after the active expulsion of this 5HT metabolite has been blocked by probenecid
or dinitrophenol (233, 234); and (b) from the initial rate of 5HIAA decline or
5HT rise after usinga MAO inhibitor (235). In the second category of methods,
isotopically-labelled substances are used (236): for example, (a) after MAO
inhibition, the rate at which 14C-labelled tryptophan and 5HTP are converted
into 5HT can be measured (61, 237); and (b) after tritiated 5HT has been
taken up by brain tissue either in vitro or in vivo (after its intraventricular
injection), the rate of disappearance of isotopic activity also illustrates
turnover (155, 238).
However the theoretical bases of these techniques for measuring 5HT
turnover are suspect (232). Firstly, the inhibition of reactions by the
relevant drugs is probably never specific and absolute (239-241). Secondly,
other metabolic pathways for 5HT (231) (see Introduction 1.2.2) provide
alternative routes whereby the pharmacological blockade of individual steps
of the principal 5HT metabolic pathway can be circumvented by 5HT or its
precursors (242, 243). The reliability of turnover studies which are inter¬
preted on the assumption that 5HT metabolism is completely and specifically
blocked at one particular stage is therefore questionable. Thirdly, the up¬
take, storage, and destruction of exogenous, isotopically-labelled substances
are assumec to exemplify the intracellular fate of endogenous substances (232,
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244, 245)i while this assumption may be tenable for isotopically-labelled
tryptophan (64), for exogenous 5HT this assumption is questionable (177,
202, 203 , 246-248). The genesis of this controversy over the fate of
exogenous 5HT may lie in discrepancies in experimental procedures, - for
example in the types of anaesthesia (202, 203), homogenization and centri-
fugation used (249, 250).
Although such technical, factors make it difficult to measure small
changes of turnover of brain 5HT convincingly, several conclusions concer¬
ning 5HT metabolism in brain can be accepted.
Firstly, 5HT turnover is faster in brain than in other tissues (61, 251).
Secondly, the regional turnover of 5HT in brain cannot be predicted from the
local 5HT concentration (252, 253). Thirdly, the rate of 5HT metabolism
varies in different regions of the brain (238, 253-255), and can be altered
by various procedures.
1.2.9 Alterations in the rate of 5HT synthesis in raphe neurones
There have been many reports of an accelerated synthesis of 5HT in
brain following the electrical stimulation of the raphe nuclei (197, 256-260)
or of regions rich in 5HT terminals (281). In the raphe neuronal terminals
of the transected spinal cord, the amount of spontaneous electrical activity
in the cord segments may determine the rate of 5HT synthesis (24, 2o2, 263).
Various drugs alter the rate of 5HT metabolism: for example, the turnover
decreases after the administration of lysergic acid (264, 265) and imipramine-
like drugs (222, 266-268); turnover increases after reserpine and lithium
(235, 269, 270).
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Id mouoamiuergic neurones, transient changes in the rate of mono¬
amine production may result from the altered activity of a constant amount
of synthesizing enzyme already present in the nerve terminals (271-273).
The biochemical mechanisms responsible for these changes may include
variations in the precursor uptake (see Introduction 1.2.3), intracellular
electrolyte concentration (274-277), cofactor and coenzyme availability
(40, 87, 278, 279), or end-product inhibition (237, 280-282). But in
noradrenergic neurones, prolonged increases in the rate of noradrenaline
synthesis result from greater amounts of synthetic enzymes being produced
by induction in the cell bodies of these neurones (283-288); this process can
be aborted by inhibiting the synthesis of ribonucleic acid and protein (108,
289-291). A similar biosynthetic mechanism may operate in 5HT-
synthesizing cells (239, 292, 293).
1.3 Conclusions
Certain conclusions can be drawn from the published work on raphe
neurones. 5HT is probably a neurotransmitter (190, 294-296). The
enzymes necessary for 5HT synthesis and breakdown, and for the synthesis
of storage vesicles are produced in the cell bodies of the raphe neurones.
Changes in the rate of 5HT formation have been detected and measured using
various techniques. Long-term alterations in 5HT-synthesis-rates may be
mediated by the protein-biosynthetic mechanisms in the cell bodies of these
neurones.
When 5HT is released from the terminals of raphe neurones, the
electrical activity of most postsynaptic neurones - such as those in the
supra., hematic nucleus - is inhibited.
13
1.4 Aims of thesis
In the present study, the technique of interference microscopy was used
with the following intentions:
a) to confirm that, in interneurones such as the median raphe
neurones, changes in nucleolar dry mass could be induced which were com¬
parable to those reported in motor neurones and neurosecretory neurones
(see Introduction 1.1);
b) to see if such changes in the nucleolar dry mass of raphe neurones
were followed by changes in the nucleolar dry mass of neurones postsynaptic
to raphe neurones, for example the suprachiasmatic neurones in the
hypothalamus (see Introduction 1.2.7);
c) to ascertain whether or not drug-induced changes in the nucleolar
dry mass of the median raphe and suprachiasmatic neurones could be
related to the concurrent alterations in 5HT metabolism reported by other
investigators using other techniques.
2. GENERAL ME THODS.
2.1 Preparation of animala
Unless otherwise stated, male albino rats, aged 3-3^ months and
weighing 250-300 gm were used in the experiments. They were grouped
4-6 per cage, and allowed free access to water and rat pellets. After
arrival in the departmental animal house, the rats were allowed at least
10 days to adapt before any experimental procedure was started. Drugs
and control solutions were administered as described for each experiment.
Daily intraperitoneal injections were given at 09.00 hours; in some experi¬
ments, a second injection was given at lo. 00 hours. In most cases, animals
were hilled between 11.00 hours and 13.00 hours.
The animals were killeu by exsanguii*ation under light ether anaesthesia.
2.2 Preparation of specimens for microscopy
A longitudinal midline incision was made in the scalp. The brain was
exposed using bone nibblers to remove the vault of the skull. Two transverse
cuts were made in the brainstem, vertical to the base of the skull, above and
below the superior corpora quadrigemina. A thin slice of brainstem tissue,
about 1 mm thick, was then freed from underlying tags of tissue, lifted out,
and placed in a watch-glass containing cold homogenization medium. With a
dissecting microscope, the median raphe region was identified by its relation¬
ship to obvious adjacent structures (Fig. 2.2.a.){297). A small block of
median raphe neurone tissue (1 x 0.5 x 0.25 mm) was excised from this
region (Figs. 2.2.b.-d.). No other raphe nuclei were examined.
Fig. 2.2.a.: Diagram of brainstem, transverse section. Abbreviations
represent, cerebral aqueduct (c.a.), dorsal raphe nucleus (d.r.n.),
superior cerebellar peduncle (s.c.p.), tectospinal tract (t.t.),
median raphe nucleus (m.r.n.), trigeminal nerve, sensory root
(t.), and raphe (r.)
Fig. 2.2.b.: Transverse section of brainstem, stained by H & E, showing
median raphe region partially excised; magnification x 18.
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Fig. 2.2.C.: Transverse section of median raphe region, partially excised,
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Fig. 2.2.d.: Section of median raphe region, totally excised, prepared as
in Fig. 2.2.c.
Fig. 2.2.e.: Diagram of medial aspect of bisected hypothalamus; abbreviations
represent thalamus (t.), anterior commissure (a.c.), preoptic
nucleus (pr.n.), optic chiasm (o.c.), suprachiasmatic nucleus
(s.n.), ventromedial nucleus (v.n.), arcuate nucleus (a.n.),
dorsomedial nucleus (d.n.), posterior nucleus (po. n.), and
mamillary nucleus (m.b.).
Fig. 2.2.f.: Preparation of medial hypothalamus, stained by H & E, magnifi¬
cation x 25.
To obtain tissue containing hypothalamic nuclei, the rest of the
brain was removed from the skull, placed in a watch-glass containing
homogenization fluid, and then viewed down a dissection microscope (x 12
magnification). The base of the brain was bisected by means of a midline
incision which ran posteriorly through the hypothalamus from a point
directly anterior to the optic chiasm. The underlying cavity of the third
ventricle was seen. The two brain halves were gently cut apart, leaving
the medial (ventricular) surface of each hypothalamus exposed.
The various hypothalamic nuclei were identified by means of adjacent
landmarks (Figs. 2.2.e. -f.)(297). Small blocks of tissue (0.5mm cubed) were
excised as indicated later in the text. These tissues contained the supra-
chiasmatic, arcuate, preoptic, ventromedial, dorsomedial ana posterior
nuclei. Usually the corresponding tissues from both halves of the hypotha¬
lamus were pooled.
Each block of tissue was transferred to a small homogenizer (Fig.
2.2.g.) containing approximately 2.5/d of homogenization fluid. The compo¬
sition of this fluid was: 0.34 M sucrose, 0.002 M MgCl , 0.001 M KC1, and
0.005 M Tris, adjusted to pH6.5 with IN HC1 (298). After gentle mechanical
disaggregation of the tissue, the resulting suspension of isolated neuronal
nuclei was transferred by Pasteur pipette to a glass slide (specimen slide)
ana covered by a glass coverslip. A similar droplet containing only the
homogenization fluid was pipetted on to a matching slide and covered by a
matching coverslift to act as a reference slide.
Fig. 2.2.g.: Small glass homogeniser with plunger; each small division
on the scale represents 1 mm.
Fig. 2.3.b.: Photomicrograph of intraglial nucleus.
16.
2.3 Identification and aelection of nucleoli for measurement
The isolated nuclei of neurones were readily distinguished from
those nuclei within neurones or neuroglia (Figs. 2.3.a. andb., Fig. 2.4.3.).
Compared to glial nuclei, the nuclei of neurones were larger, their nucleo¬
plasm was less granular, and their nucleoli were more prominent.
To avoid any tendency to select for photography those neuronal
nuclei with large nucleoli, all isolated neuronal nuclei within each micro¬
scopic field were photographed. Another field was then examined in a
different part of the slide according to a predetermined pattern, so that
examples of neuronal nucleoli from all parts of the slide could be randomly
selected and their dry mass measured.
2.4 Measurement of nucleolar dry mass of isolated neuronal nuclei
2.4.1 Analysis of measurements
Isolated neuronal nuclei were identified and their individual values for
nucleolar dry mass were calculated. To obtain each pooled mean value for
the nucleolar dry mass of raphe neurones, usually between 150 and 350
nucleoli from 4-6 rats were observed. For the various hypothalamic
neurones, pooled mean values were based on the dry mass measurements
of 50 to 100 neuronal nucleoli from the same rate. In the experiments
described as preliminary, fewer observations were made. The results for
pooled mean nucleolar dry mass of all neurones were evaluated statistically
using Student's test. Experimental groups were compared with control
groups in order to obtain "p" values; "N. S." represents "no significant
change".
2.4.2 Interference microscopy - theory
The interference microscope provides a method for interpreting the
retardation imposed on a beam of light by a translucent body or organelle
in its path in terms of its dry mass: dry mass is the mass of substance
other than water. Two beams of light are of equal frequency and originally
in phase. One beam (the object beam) traverses the organelle being
examined, while the other (reference beam) provides a comparison beam.
When these beams are recombined and allowed to interfere, a fringe or
banded pattern is produced by the alternating zones of constructive and
destructive interference of the two beams. If the organelle is denser than
the surrounding medium - say water - and has the higher refractive index,
the beam traversing the organelle will be retarded. The image of the
organelle is seen by interference contrast; the optical path difference
between the two beams is shown by the lateral shift of those interference
bands passing through the organelle. The magnitude of this optical path
difference (OPD) depends partly on the dry mass and refractive index of
the translucent organelle. The mathematical calculations and formulae,
from which the equation for the dry mass of neuronal nucleoli is derived,
can be found in Appendix I.
The use of interference microscopy to measure the dry mass of
cells, nuclei and nucleoli is justified by the close agreement between the
Fig. 2.4.3.: Photomicrograph of an isolated raphe neuronal nucleus,
with nucleolus; illumination firstly with fringe pattern of
bands, secondly with uniform background.
Fig. 2.4.4.: Microdensitometric traces, - one scan (passing through the
centre of the nucleolus in an isolated neuronal nucleus) is
superimposed upon a second scan (portraying the fringe pattern
of interference bands); the abbreviations are explained in text,
section 2.4.4.
values for specific refractive increment and dry mass obtained by this
technique and by biochemical analysis (299, 300), X-ray microradiography
(301-304), ultraviolet microabsorption (303 , 305) and refractometry (306).
2.4.3 Interference microscopy - technique
In these investigations the Leitz double-beam interference microscope
was used, with objectives X 50/0.85 and condensers NA 0.5. The procedure
was similar to that described elsewhere (16, 20, 21). The specimen and
reference slides were placed on the appropriate stages of the microscope.
Having obtained the fringe pattern of alternating dark and light bands
(Fig. 2.4.3.), white light was used to identify the "zero order" band, which
is a white band flanked symmetrically first by black bands and then by a
sequence of coloured bands. Along the zero order band the optical path
differences (OPD) between light of all wavelengths is zero; with this band
in the centre of the field, the contrast of the fringe pattern is maximal.
After the illumination had been switched to monochromatic light (546 nm
wavelength), an isolated neuronal nucleus was selected for photography
and brought into focus. The bands were separated until the field was
uniformly illuminated; at this juncture, there was no variation in OPD
over the field. The optimal conditions for subsequent measurements
were obtained when the centre of the nucleolus and the background were
of equal brightness; under these circumstances, the relationship between
OPD and light intensity was linear (16). Photomicrographs were taken
firstly of the nucleolus with uniform background illumination; and secondly
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of the adjacent clear field, with the original fringe pattern (Fig. 2.4.3.).
Photomicrographs were taken on Kodak Pius X 35 mm film; they
were developed using Kodak 19b developer solution. Having been washed
and dried, the films were scanned by microdensitometry. Objects lying
on the object plane of the interference microscope were thus portrayed in
density profile on the microdensitometer trace at a magnification of 4.2 x
103.
2,4.4 Microdensitometry - technique
Photographic film containing the photomicrographs of the neuronal
nuclei was placed on the specimen table of the Joyce-Loebl Automatic
Recording Microdensitometer Mk IHe. The photomicrographs were scanned
in the long axis of the film.
The instrumental settings were:
grey wedge range: 0-2D
objective magnification: x 22
scanning slit aperture (width x height): 140 x 300 nm
arm mtio: 20 to 1
In the first scan, a tracing of the nucleolus within its nucleus
was obtained. The nucleolar profile selected was that describing the
maximal nucleolar width in the axis of scan. The edges of the nucleoli
were easily seen on the scan, and the outermost rims of each nucleolus
were marked on the density tracing paper. The distance between these
marks was the nucleolar diameter, d cm.
Table 2.4.5.
NUCLEUS Dm/d Standard error No
Raphe 0.0667 0.0029 1.415
Suprachiasmatlc 0.050 0.0023 1.399
Arcuate 0.053 0.0017 1.402
Dorso-medial 0.047 0.0015 1.396
Ventro-medial 0.050 0.0018 1.390
Posterior 0.052 0.002 1.401
Preoptic 0.047 0.002 1.396
Dm : nucleolar OPD
d : nucleolar diameter
No : nucleolar refractive index (corrected)
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Superimposed on this first tracing was a second trace, obtained
by scanning the photomicrograph of the banded field adjacent to the
isolated nucleus*
Using these traces (Fig. 2.4.4.) the following measurements were
made for each nucleolus:
d = nucleolar diameter
La = 1 wavelength of the light used (546 am), or the OFD
between equivalent points of intensity on adjacent
bands of fringe pattern,
a = measure of optical retardation imposed by nucleolus
a/La = peak nucleolar OFD.
2.4.5 Sources of error in procedures
There is negligible loss of substance from the nucleoli in isolated
nuclei (18). In the present investigation, when slides of isolated neuronal
nuclei were examined directly and up to six hours after their preparation,
the values obtained for mean nucleolar dry mass were comparable.
The measurement of nucleolar dry mass by interference microscopy
is subject to variables. Of these, the corrected values for nucleolar
refractive index (No) were estimated from samples of 50 nucleoli randomly
selected from each group of neurones studied (Table 2.4.5.). Of the
sources of error due to the optics of the microscope, light scattering and
glare were unlikely to be significant under the conditions of these
experiments (20, 21, 307).
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During microdensitometry, the potential observer error inherent
in determining accurately the nucleolar rime - and hence in calculating
the value for nucleolar diameter - was minimized by the author performing
all the measurements. When nucleoli were scanned twice in these circum¬
stances, the values for diameter were accurately reproduced.
Hence the effects of the potential variables and sources of error
were negligible. Nevertheless their existence favours the interpretation
of the results in this thesis as describing trends in nucleolar dry mass
values, rather than the absolute values.
2.5 Drugs used in investigations
1) Beserpine (lmg/ml) in stabilized aqueous solution: Halewood
Chemicals Ltd., Staines, Middlesex, England.
2) Oxypertine ('Integrin'): Winthrop Labs., Surbiton-upon-Thames,
U.K.; as l-(2-(5,6~dimethoxy-2-ruethylindole-3-yl)ethyl)-4-
pheny1piperazine.
3) Nialamide ('Niamid') Chas. Pfizer & Co., New York; as
nialamide (l-(2-(benzylcarbamyl)ethyl)-2-isonicotinoyl-hydrazine)
monochlorlde.
4) Tranylcypromine ('Parnate'): Smith, Kline & French Labs. Ltd.,
Welwyn Garden City, Herts.
5) Imipramine ('Tofranil'): Geigy (U.K.) Ltd., Macclesfield,
Cheshire; as the 5-(3-dimethylaminopropyl)-10,11-dihydrodibenz
(b,f)azepine hydrochloride; 25mg per 2ml vial.
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6) Desipramine ('Fertofran'): Geigy (U.K.) Ltd.; as 10,11-dihydro-
5~(3-methylamiriopropyl)dibenz(b,f)azepine hydrochloride; 25mg
per 2ml vial.
7) Lithium Carbonate: BDH Chemicals, Poole, England.
8) 5HT creatinine sulphate: Sigma London Chem. Co. Ltd., Kingatoa-
upon-Thames, England.
9) 6-hydroxydopamine HBr: Sigma Ltd.; as 2,4,5-trihydroxyphen-
ethylamine.
10) Noradrenaline acid tartrate: Winthrop Labs.
11) Histamine acid phosphate: BDH Chemicals.
12) Tryptophan (L-tryptophan): BDH Chemicals.
13) Phenylalanine (L-jg -phenylalanine): BDH Chemicals.
14) PCPA (p-chloro-DL-phenylalanine): Koch-Light Labs. Ltd.,
Colnbrook, Bucks, England.
15) Diamorphine (lmg per 1ml ampoule) in aqueous solution: Dept.
of Pharmacy, Royal Infirmary, Edinburgh.
16) Barbitone Sodium: Mackenzie & Co. Ltd., Edinburgh.
17) Cortisone acetate ('Cortisyl'): 25mg/ml. Roussel, London.
18) Testosterone propionate, 50 mg/ml in ethyloleate 20%, arachis
oil 80%: Evans Medical Ltd., Speke, Liverpool.
19) Almond Oil B.P.: Mackenzie & Co.
SECTIONS. CHANGES IN NUCLEOLAR DRY MA88 OF
VARIOUS INTERNEURONES IN THE CENTRAL NERVOUS
SYSTEM OF THE RAT
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3.1 The nucleolar dry mass response of raphe neurones and of
various neurones in the hypothalamus to the drug-induced depletion
of brain 5HT
3.1.1 Introduction
The aims of this experiment were firstly to produce and measure
changes in the nucleolar dry mass of those interneurones principally
concerned in brain 5HT metabolism, i. e. the raphe and suprachiasmatic
neurones; secondly to test the specificity of those changes by examining
concurrently the nucleoli of various other interneurones which are not
involved in brain 5HT metabolism.
Reserpine combines with (184, 308, 309) and disrupts (174, 310)
the vesicles which contain most of the 5HT in raphe neurones (see
Introduction 1.2.5)(162,231). The 5HT thereby liberated (166, 167) is
inactivated by cytoplasmic MAO (126), and the brain concentration of 5HT
falls while that of its metabolite 5HIAA rises (74, 311,312); 5HT histo-
fluorescence in neurones disappears (126, 135). Subsequently the rate
of 5HT synthesis increases (235). Hence it was of interest to investigate
the involvement of raphe neuronal nucleoli in the restoration of brain 5HT
content which follows the reserpine-induced depletion.
Whereas reserpine also depletes neuronal catecholamines by
a similar mechanism (123, 132, 147), oxypertine is an indole derivative
which rapidly decreases the catecholamine content of hrain without
altering brain 5HT metabolism (313, 314-313). By observing the
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nucleolar dry mass of raphe neurones after the administration of oxypertine
it was hoped to verify the specific nature of the raphe neuronal response to
reserpine.
3.1,2 Methods
Two experiments with reserpine were carried out. In the first
experiment, rats were given reserpine lmg daily for up to 9 days ("high-
dose" reserpine) by intraperitoneal injection. In the second experiment,
rats were given intraperitoneal injections of reserpine, 0.5mg, daily
for up to 10 days ("low-dose" reserpine); after this time the drug was
withdrawn, and the rats were kept for up to 10 days more. Control animals
in both groups were given intraperitoneal injections of appropriate volumes
at linger lactate solution.
During these experiments, rats were killed in batches at various
stages (see Results 3.1.3). The dry mass response of nucleoli from raphe,
suprachiasmatic, posterior, preoptic and ventromedial neurones was
observed using the interference microscope.
In the oxypertine experiment, rats received a suspension of oxy-
pertine (2mg in 1ml Ringer lactate) by intraperitoneal injection daily for
7-8 days. Control animals received similar injections of Ringer lactate






Fig. 3.1.A. Raphe and guprachiasmatic neurones: columns indicate pooled
mean nucleolar dry mass, with standard errors; rats received





Fig. 3.I.B. Raphe and suprachiasmatic neurones: data illustrated as in
Fig. 3.1.A., but with reference to the administration and sub¬







Fig. 3.l.C. Various other neurones: data as in Fig. 3.1.B.
Fig. 3.I.D. Raphe neurones: data presented as in Fig. 3.1.A., but experi¬
mental animals received oxypertine for 7-8 days.
TABLE3.1. NUCLEUS Raphe Supra- chiasmatic (S.C.) Raphe S.C.
DRUGG OUP(with numberofanimals) Control,(3) Reserpined4-5,(5) Reserpined5-9,(4)1^3 Control,(3) Reserpined5-6,(2) li*sad8—9,(3) Control,(4) Reserpined4,(2) 05YV^d8-10,(4) Withdrawd2,(3) d4-6,(5) d9.(3) Control,(4) Reserpined4,(2)OSd8-10,(4) Withdrawd2,(3) d4-6,(5) d9.(2)





















































TABLE3.1.(eontd.) NUCLEUS Posterior Pre-optic Ventro¬ medial






























107N.S 41N.S 116 44N.S 59N.S 64N.S. 108N.S 41N.S 116 470.02-0.01 800.005-0.001 690.05-0.025 109N.S 29N.S. 293 386N.S
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3.1.3 Results
In these experiments (Figs. 3.1.A. & B.f Table 3.1) reserpine
affected a dose-related increase in the nucleolar dry mass of the raphe
Deurones.
' ' s
In the low-dose reserpine experiment, the increased nucleolar dry
.! ■ • y
mass of the raphe neurones returned to normal value? after reserpine
administration had ceased; but up to the ninth day of withdrawal, no
"overshoot" was apparent (Fig. 3.1. B.).
With low-dose reserpine, the nucleolar responses of the raphe
neurones preceded similar changes in the nucleolar dry mass of the supra-
chiasmatic neurones (Fig. 3.I.B.). However no significant changes were
seen in the supr&chiasmatic neurones after high-dose reserpine (Fig. 3.1.A.).
The changes seen in the ventromedial neurones after low-dose reser¬
pine bore no relationship in time or direction to the responses of the raphe
and suprachiasmatic neurones. No significant changes were seen in the
posterior or preoptic neuronal nucleoli during this experiment (Fig. 3.I.C.).
The administration of oxypertine to rats for 7-3 days did not alter
the nucleolar dry mass of their raphe neurones (Fig. 3.I.D.).
In the rats receiving high-dose reserpine, sedation was marked.
Most rats lost weight and suffered from diarrhoea; some also developed
crusting around the nose and eyes. The mortality rate was maximal between
days 4 and 6; during the experiment, about one rat in four died.
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The rats receiving low-dose reserpine did not show these florid
signs. However they lost weight: their initial average weight ot about
300 gm each declined to around 220 gm at day 4 of reserpine, rose again
to about 250 gm at days 8-10, and was about 270 gm at the end of the
experiment. Water intake also declined: normal intake averaged about
25ml/rat/day; by day 2 intake was reduced by 50%, and it was only 25%
of normal at day 5; but 2 days after reserpine had been discontinued, water
intake was again normal. Food intake was not measured, but was probably
reduced while the animals were receiving reserpine.




These experiments demonstrated that the raphe interneurones con¬
cerned in 5HT synthesis showed changes in their nucleolar dry mass after
the administration of a 5HT-depleting drug. The time-course of these
nucleolar changes was similar to that reported for the nucleolar responses
to prolonged stimulation in motoneurones and neurosecretory cells (see
Introduction 1.1.).
The increased dry mass of raphe neuronal nucleoli after reserpine
can be interpreted as a sign of increased riboscme and protein synthesis
(see Introduction 1.1). In the morphologically-similar noradrenergic
neurones (317), reserpine also promotes the destruction of noradrenaline
by damaging the storage vesicles (235, 318). During the subsequent resto¬
ration of the amine content of these neurones (25), a slow increase in the
amount of noradrenaline-synthesizing enzymes is found in their cell bodies
(109 , 319-321) (see Introduction 1.2.9); the restoration of noradrenaline
content is delayed when inhibitors of protein and UNA synthesis are
administered (108, 289 , 321). In raphe neurones a similar, dose-dependent
increase in the production of 5HT-synthesizing enzymes (269, 293, 322)
probably contributes to the accelerated formation of 5HT after reserpine
(235). This view is supported by the nucleolar changes observed in the
present study, since the 5HT-synthesizing enzymes are formed mainly if
not entirely within the cell bodies of the raphe neurones (see Introduction
1.2.3).
The damage caused by reserpine to the storage vesicles is probably
irreversible (189). Therefore for the restoration of brain monoamine
levels, protein components for new vesicles must be synthesized in the
nerve cell bodies, and then transported to the nerve terminals (see Intro¬
duction 1.2.5). These processes, which take place some 2-5 days after
giving reserpine, may also be linked with the increased nucleolar dry mass
of the raphe neurones (317).
Reserpine induces anorexia (323). The decline in brain 5HT concen¬
tration resulting from a low-tryptophan diet is more proroun. «d when reser¬
pine is also given (324). In the high-dose reserpine experiment in this
investigation, food intake was severely depressed: it is possible that the
concurrent dramatic increase in the nucleolar dry mass of the raphe neurones
was a response to the low brain 5HT concentration (see Concluding Discussion
4.1), which in turn resulted from both a decreased synthesis and an enhanced
destruction of 5HT.
According to the evidence of histofluorescence and other anatomical
studies (29, 32, 213), the suprachiasmatic nucleus includes many 5HT-
containing nerve endings, but none containing noradrenaline; around 5% of
the boutons in the nucleus may contain 5HT (156). During the administra¬
tion of reserpine, the amount of 5HT in cerebral ventricular perfusates
from the experimental animals does not increase as the brain 5HT con¬
centration plummets (325); this indicates that 5HT from the disrupted
vesicles of raphe neurones is metabolized by MAO intraneuronally, and is
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net released into the synaptic spaces (147). Hence one probable effect of
reserpine is to diminish the amount of 5HT released from the raphe neuronal
terminals on to the suprachiasmatic neurones (326). When 5HT is released
on to suprachiasmatic neurones, either directly by iontophoresis or indirectly
by stimulating electrically the raphe neurones, the spontaneous firing of the
suprachiasmatic neurones is inhibited (see Introduction 1.2.7). Therefore
during the administration of low-dose reserpine, the increased metabolic
activity of suprachiasmatic neuronal nucleoli may be a consequence of
attenuating the normal degree of 5HT inhibition of these neurones (327).
Moreover, with the cessation of reserpine administration and the consequent
replenishment of 5HT in raphe neuronal terminals, the normal degree of
trans-synaptic inhibition of the suprachiasmatic neurones could be restored.
This sequence of events is compatible with the restoration of the normal
nucleolar dry mass values for suprachiasmatic neurones after reserpine
withdrawal.
The absence of any significant response by supracbiasmatic neurones
to high-dose reserpine is difficult to explain. Perhaps this dosage provoked
an exceptionally vigorous biosynthetic response by the raphe neurones - as
was evinced by the greater increase in their nucleolar dry mass -; an
accelerated production of vesicles, synthesizing enzymes and ultimately
of 5HT itself may have sustained the release of 5HT from a small, reserpine-
resistant pool of 5HT (203, 328) in the raphe terminals in the suprachiasmatic
nucleus; in noradrenergic neurones, functional recovery after reserpine is
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associated with the presence of a low concentration of noradrenaline - the
small, functional pool in the terminals (134, 188, 329, 330). Alternatively
at this dosage of reserpine, hormones with effects antagonistic to those of
5HT may have been released from other terminals in the suprachiasmatic
nucleus. This may have happened as a specific response to reserpine,
as a consequence of the anorexic and sedative effects of reserpine (323,
331), or as a response to the general stress associated with the repeated
injections and dehydration; for besides its effects on 5HT and noradrenaline
in neurones, reserpine alters the metabolism of acetylcholine in brain (332-
334). Reserpine also enhances the secretion of ACTH from the anterior
pituitary (335): ACTH and corticosteroids increase 5HT synthesis in brain
": 3
(336).
In the other hypothalamic nuclei studied, 5HT-containing terminals
are scanty while noradrenergic terminals are more abundant (29). Only
the neurones of the ventromedial nucleus showed nucleolar changes during
the administration of reserpine; these changes differed qualitatively from
• '1
the responses of the raphe and suprachiasmatic neurones. Alterations in
the nucleolar dry mass of the neurones in the ventromedial nucleus develop
rapidly after adrenalectomy and after surgical stress (21). Rut because
the physiological functions of these neurones are not known, the significance
of their nucleolar changes cannot be evaluated.
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Like reserpine, oxypertine has sedative properties (243, 337). Li
various rodents, oxypertine rapidly decreases the catecholamine content
of brain; this decrease is prevented by MAO inhibition. Hence oxypertine
is considered to exert a reserpine-like action on cateehclamine-containing
vesicles but not on 5HT-containing vesicles, since 5HT metabolism is not
altered (313-316, 338). The unchanged nucleolar dry mass of the raphe
neurones in the present study supports both this view and the contention
that the nucleolar changes in the raphe neurones after reserpine were not
the consequence of noradrenal iue depletion in the brain.
3.1.5 Conclusions
Increments in the nucleolar dry mass of the raphe and suprachiasmatic
interneurone s were produced by the administration of reserpine. Inter¬
pretations of these changes were compatible with the known alterations of
5HT turnover and of enzyme synthesis after reserpine. Changes in the
nucleoli of the ventromedial neurones could not be explained. No other
.
neurones showed nucleolar changes. Oxypertine did not alter the
nucleolar dry mass of raphe neurones.
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3.2 Changes in the nucleolar dry mass of raphe neurones in response
to drugs which inhibit neuronal MAO, and to various stresses
3.2.1 Introduction
The amount of 5HT in brain is increased when MAO Inhibitors are
used to block the main metabolic pathway for 5HT degradation (25, 31, 202).
The nucleolar responses of raphe and other neurones to the administration
of these drugs were investigated. The drugs used were nialamide alone
(126) and tranylcypromine alone (331, 339). In addition., nialamide was
given together with reserpine, in order to observe the effect of increasing
the concentration of "free" cytoplasmic 5HT in raphe neurones, while
decreasing the amount of 5HT bound in their vesicles (132, lb3, 211, 340).
In these ancl other experiments, drugs were prepared in aqueous and
oily solvents, some of which were not available for use as control injections.
In the reserpine experiment (Results 3.1.3) the water intake of the rats was
reduced. Hence it was decided to ascertain also whether or not physiolo¬
gical responses to the stresses of repeated parenteral injections and of
dehydration might influence the nucleolar dry mass of raphe neurones.
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3.2.2 Methods
Three experiments were performed using MAO inhibitors. Nialamide,
lOmg dissolved in 0.2ml saline, was given to each rat daily for up to 10
days by intraperitoneal injection. Tranylcypromine, 5mg was given similarly
for 8 days. Nialamide, 50mg alone on day 1 but 25mg when combined with
reserpine 0.5mg subsequently, was given in 0.5ml saline daily for up to
7 days. Control animals from each group were given intraperitoneal
injections of 0.5ml saline daily for 5-9 days. At the end of these experi¬
ments the rats were killed. The nucleolar responses of raphe, supra-
chiasmatic, dorsomedial and arcuate neurones were scrutinized as
described earlier. In the tranylcypromine experiment, only the raphe
neurones were examined.
For the experiments on the effects of stresses, rats were given
intraperitoneal injections (lml daily) of almond oil or of Ringer lactate
solution. Other rats were handled similarly but received no injections.
Tissue containing media, raphe neurones was excised from the
brains of rats which had been deprived of drinking water for 5 days;
similar tissue was also obtained from the brains of control animals (see
Footnote).
In these stressed animals, the nucleolar parameter of only the raphe
neurones was measured.
(Footnote: these tissue samples were obtained with the cooperation of






Fig. 3.2.A. Raphe neurones: animals received drugs as shown in columns;
these represent pooled mean nucleolar dry mass with standard
errors.
Fig. 3.2.B. Raphe neurones: data represented as in Fig. 3.2.A., but





































Fig. 3.2.D. 6 £. Raphe neurones: columns indicate pooled mean nucleolar
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Tranylcypromine and nialamide produced no significant changes either
in the raphe neuronal nucleoli or in the hypothalamic neurones studied. The
combination of nialamide with reserpine also proved ineffectual on these
neuronal nucleoli (Figs. 3.2.A.-C., Table 3.2.).
No significant changes were seen in the nucleolar dry mass of the
raphe neurones after repeated injections of aqueous and oily solutions, or
after dehydration (Figs. 3.2.D.-E., Table 3.2.).
During the administration of nialamide, the behaviour of the rats
(assessed subjectively) began to alter at day 3: the animals became very
reactive to light touch, they escaped from the cages with alacrity during
handling, and they frequently adopted aggressive postures towards each
other - standing on their hind legs and swaying from side to side. Other*
wise their physical condition remained good. The behaviour of the rats
receiving tranylcypromine was less remarkable, while the rats receiving
nialamide and reserpine combined were more lethargic.
The animals in both stress experiments appeared healthy and
beha ed normally during the investigations. After 5 days of dehydration,
the average weight loss was about 25%.
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3.2.4 Discussion
After MAO inhibition (with or without reserpine) the 5HT content and
Mstofluorescence intensity of the raphe nuclei increase (25, 200, 211), -
although an increased fluorescence in the median raphe nucleus may not be
evident (341). The rate of 5HT synthesis probably does not alter (200, 336,
342), or it may decline (237, 280-282) (see General Discussion 4.1). The
resting firing rate of raphe neurones is depressed (234, 343, 344). In the
present study the unaltered nucleolar dry mass of the raphe neurones indicates
that whatever the other changes were in raphe neuronal metabolism, ribosomal
synthesis does not alter significantly when MAO inhibitors are given for 7 days
(Figs. 3.2.A. & B.). In an earlier experiment, reserpine caused an
increment in the nucleolar dry mass of raphe neurones (see Results 3.1.3).
In this experiment, reserpine given with nialamide failed to effect a similar
change. This finding is of interest, in view of the report that, in noradrenergic
neurones, the trans-synaptic induction of tyrosine hydroxylase by reserpine
is blocked when MAO is inhibited (321).
There is some controversy as to whether the excess cytoplasmic
5HT in raphe neurones spills out across the neuronal membrane during MAO
inhioitxou. In vivo, the administration of MAO inhibitors alone, or with
reserpine, increases the normal release of 5HT from brain tissue into
ventricular perfusates (193, 325); after a massive dose of nialamide
(5O0mg/kg body weight intraperitoneally) extracellular 5HT histofluorescence
is reported (23 , 345). However in the presence of these drugs, there is an
uni npeded accumulation and retention of tritiated 5HT by brain slices (137).
Moreover, studies using histofluorescence and biochemical techniques
indicate that with the dosages of MAO inhibitors comparable to those used
in the present study, the raphe neuronal membrane pump may prevent the
accumulating intracellular 5HT from leaking out and increasing the extra-
neuronal levels of 5HT (25, 340). A similar situation is found in noradrenergic
terminals: despite pretreatment with reserpine and nialamide, a sustained
noradrenaline fluorescence can still be produced by the intraneuronal accumu¬
lation of exogenous noradrenaline (346).
In the present study, the nucleolar dry mass of the suprachiasmatic
neurones did not alter after the inhibition of MAO, even with the concurrent
administration of reserpine. This evidence of their unchanged metabolic
activity is consistent with the view that, when these drugs are used in the
dosage described in the present investigation, there is no gross accumulation
of 5HT outside the raphe neuronal terminals in the suprachiasmaiic nucleus.
When reserpine in a similar dose was given alone, the nucleolar dry mass of
the suprachiasmatic neurones increased, possibly as a result of attenuating
5HT inhibition (see Results 3.1.3 and Discussion 3.1.4). But raphe neuronal
5HT is not depleted, when reserpine is given after a MAO inhibitor (211);
and there may be a continuing release of 5HT adequate to maintain the normal
degree of inhibition of the suprachiasmatic neurones. This hypothesis is
compatible with the results of the present study.
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Behavioural excitation in animals receiving MAO inhibitors has been
reported elsewhere (201) and will be discussed later (see Discussion 3.4.4).
Various stresses, including intermittent electroshock (347), horizontal
oscillation (348), handling (343), restraint and isolation (350), reportedly
alter the metabolism o£ various brain monoamines including 5HT. However
a dissenting opinion has been expressed that stress may not affect significantly
central 5HT neurones (351). This opinion is corroborated by the results of
the present study.
After 5 days dehydration, the nucleolar dry mass of rat supraoptic
neurones was markedly elevated (19); however this stress did not alter
significantly the nucleolar metabolism of the raphe neurones. Elsewhere,
repeated daily injections of saline for 16 days have been found to increase
the activity of midbrain tryptophan hydroxylase by 23% (352);- however when
the rats in the present study were given daily intraperitoneal injections of
Ringer lactate or almond oil, the absence of nucleolar changes in the raphe
neurones indicated that these particular nonspecific stresses were incon¬
sequential, insofar as the synthesis of ribosomes and protein by raphe
neurones was concerned.
3.2.5 Conclusions
Following MAO inhibition, without or with reserpine, no changes
were detected in the nucleolar dry mass of raphe and suprachiasmatic
neurones. These findings are compatible firstly with the evidence that the
rate of 5HT synthesis by raphe neurones may not change appreciably when
the concentration of intraneuronal 5HT rises; and secondly with the contention
that there is no accumulation of extraneuronal 5HT sufficient to increase
significantly the 5KT-induced inhibition of the metabolism of the supra-
chiasmatic neurones.
There were no changes in the nucleolar dry mass of raphe neurones
after rats had been stressed by repeated injections of various "control"
solutions or by dehydration.
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3.3 The effects onthe nucleolar dry mass of raphe neurones of drugs
which alter the uptake of 5HT by raphe neurons s
3.3.1 Introduction
Tricyclic antidepressant drugs inhibit the active uptake of tryptophan
and 5HT by raphe neurones (222, 264, 353, 354); the rate of 5HT synthesis
declines after their administration (266, 268). These drugs probably do not
affect the uptake or binding of reserpine in rat tissues (355).
Like the tricyclic antidepressant drugs, lithium is used in psychiatric
therapy (356, 357); after the administration of lithium, the extraneuronal
level of monoamines decreases (357, 358), and 5HT turnover is altered
(270, 359).
The effects of two tricyclic antidepressant drugs (imipramine and
desipramine), of desipramine together with reserpine, and of lithium on




In two experiments (one year apart) the tricyclic antidepressant
drugs, imipramine and desipramine, were given to rats; some rats were
also given reserpine. All drugs were administered by intraperitoneal
injection.
In the first experiment, one group of rats was given low-dose desi-
pramine (2.5mg) daily for 8-9 days* either alone or with reserpine (O.Smg)
on the second and subsequent days. A second group of rats received desi-
pramine (10 mg on alternate days), but of the five animals in this group only
one survived until day G, when it was hilled.
In the second experiment which lasted 8-0 days, some rats received
daily injections of imipramine in low (2.5mg) or high (5mg) doee& Other
rats were given high-dose desipramine (ttng) daily.
Control rats in both experiments received appropriate aliquots
either of Ringer lactate solution or of the solvent for imipramine provided
by Geigy Ltd.
In the lithium experiment, each rat was given daily intraperitoneal
injections of 30mg lithium carbonate in 1ml Ringer lactate. Control
animals received daily injections of Ringer lactate alone. The injections
were given for 10-14 days, when the rats were killed.
In all experiments, the raphe, suprachiasmntic and arcuate nuclei

















Fig. 3.3.A. Various neurones: columns indicate pooled mean nucleolar dry
mass, with standard error; drugs given are shown in the
columns.
RAPHE SUPRACHIASM. ARCUATE
Fig. 3.3.B. Various neurones: data presented as in Fig. 3.3.A., but with
different drug regimes.
RAPHE SUPRACHI ASM. ARCUATE
Fig. 3.3.C. Various neurones: data presented as in Fig. 3.3.A., but experi¬






































































































Apart from the single rat receiving lOmg desipramine on alternate
days, the nucleolar dry mass of raphe neurones in all animals receiving
tricyclic antidepressant drugs was decreased (Figs. 3.3.A.-B., Table 3.3.).
This decrement of the nucleolar dry mass was more significant after low
doses of the drugs than after high doses: nucleolar dry mass decreased by
14-15% against 9-10% respectively. In the regime of desipramine lOmg on
alternate days, there was no nucleolar response (Fig. 3.3.A.); however
because of the high mortality in this experiment, this result was obtained
from only one animal; this result, therefore^ was recorded in the thesis
merely because it indicated the same trend in the changes in nucleolar
parameter as was found after the other experiments using tricyclic drugs, -
namely, that high doses of these drugs had less effect on the nucleolar dry
mass of raphe neurones than did low doses. There was no decrement in
the nucleolar dry mass of raphe neurones after desipramine and reserpine
combined i
In contrast to the raphe neurones, the nucleolar dry mass of the
suprachiasmatic neurones was more depressed by the high doses of desi¬
pramine and imipramine than by the low doses (Figs. 3.3. A. & B.); after
desipramine and reserpine combined, the decrement was not significant.
In the arcuate neurones, the nucleolar parameter tended to decrease
after these drugs, but the decrements were not statistically significant
(Fig. 3.3.B.).
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After lithium, the nucleolar dry mass of the raphe neurones was
increased (Fig. 3.3.C.). The changes in the nucleolar parameter of
suprachiasmatic and arcuate neurones were not statistically significant.
Apart from the considerable mortality in the high-desipramine series
(lOmg on alternate days) which has already been described, there was little
sign of drug toxicity in these experiments. Some rats receiving tricyclic
antidepressant drugs,especially low-dose desipramine, became exception¬
ally alert and reacted excessively to various auditory and tactile stimuli.
The rats receiving lithium became increasingly excitable from day 8 onwards.
3.3.4 Discussion
The effects of tricyclic antidepressant drugs include: diminished
electrical and synthetic activity in raphe neurones, extraneuronal accumu¬
lation of 5HT resulting from the inhibition of the membrane pump for mono¬
amines, and altered activity of postsynaptic neurones.
3.3.4.1 Decreased raphe neuronal activity : shortly after the
administration of imipramine, the spontaneous firing rate of raphe neurones
decreases; this inhibition lasts for over 30 minutes (343,3i0). The
diminished impulse activity in the raphe neurones is accompanied by a
decreased breakdown of 5HT in their terminals: for example, the reten¬
tion of exogenous, isotopically-labellea 5HT in brain is prolonged when
tricyclic drugs are given after the intracisternai dose of 5HT (136, 202);
there is also a slower diminution of the endogenous 5HT content of raphe
terminals in the suprachiasmatic nucleus, if further 5HT synthesis is
inhibited (222, 361). The rate of 5IiT synthesis also declines (263, 267).
when probenecid is used to block the egress of 5HIAA (see Introduction
1.2.8), the slower rate of turnover is evident from the decrease in 5HZAA
and 5HT content of brain which follows the administration of tricyclic
antidepressants (266, 268, 353). The long-term administration of imi¬
pramine (20mg/kg intraperitoneally for 10 days) results in the continuing
decline of the levels of 5HT and 5H1AA in almost all areas of the brain (362).
However after much smaller doses of imipramine (lOmg/kg every 48 hours
for 7 days), the tryptophan hydroxylase activity in rat midbrain does not
change (322).
The indications that with tricyclic antidepressant drugs the
electrical and metabolic activities of raphe neurones are both inhibited,
are compatible with the finding of the present investigation that the nucleolar
parameter of these neurones is also decreased. The observation that the
lower doses of tricyclic antidepressants in these experiments were more
effective in causing these changes than the high doses or the reserpine-
desipramine combination is discussed later (see Discussion 3.3.4.3 and
Concluding Discussion 4.1).
3.3.4.2 Extraneuronal accumulation of 5HT: tricyclic antidepressant
drugs inhibit the membrane pump for monoamines of many cells including
monoaminergic neurones, pericytes, and endothelial cells (363, 365). In
one study using vas deferens tissue, the neuronal accumulation of exogenous
5HT decreased by 62% and 57% after using desipramine and imipramine
respectively (366); in brain slices the uptake of 5HT also declines (137,
368), the percentage inhibition after exposure to desipramine and imipramine
being 40-70% depending on drug dosage (247). After exposure to these
drugs, brain synaptosomes take up less exogenous 5HT in vitro (204, 369-
371); in vivo, the accumulation by raphe neurones of 5HT given by intra¬
ventricular injection is also reduced (211, 370).
Accompanying this inhibition of the membrane pump for monoamines,
there is a less effective recapture of 5HT released from 5HT-containing
brain tissues. There is a faster efflux of unmetabolized, tritiated 5HT
which had been accumulated previously by these tiff u.eg from the incubation
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medium (367); similarly, imlpramine inhibits the recapture and subsequent
breakdown by intraneuronal MAO of the endogenous 5HT released sponta¬
neously or when raphe neurones are stimulated electrically (340, 354).
The findings of histofluorescence microscopy provide further confirmation
of these processes: with MAO inhibited, tricyclic antidepressants cause
5HT fluorescence to increase outside raphe neuronal terminals, axons and
cell bodies; if reserpine is also given, a similar increase in extraneuronal
fluorescence is seen, but intraneuronal fluorescence declines (200, 340, 370).
Tricyclic antidepressant drugs may also promote a decline in the
raphe neuronal content of 5HT by reducing the storage function of the
terminals' vesicles: these vesicles are enveloped by a membrane which
contains a monoamine pump mechanism sensitive to desipramine and
imipramine (372 , 373).
In some studies of 5HT uptake by brain synaptosomes (369, 370),
brain slices (137, 247, 368) and intact brain (177, 210, 354), the pump-
blocking action of imipramine far exceeds that of desipramine; occasionally
the latter drug is almost impotent (340, 374) unless given in very large
doses, - for instance 50mg/kg body weight or more by intraperitoneal
injection (369). In human brain imipramine is readily converted to
desipramine (375); in rat brain, the rate of this conversion by N-demethy-
lation depends on the strain of rat used (376). In the present study, in which
desipramine proved the more effective inhibitor of raphe neuronal nucleolar
metabolism, the degree of this conversion was not studied.
3.3,4.3 The responses of postsynaptic neurones: the reuptake of
5HT by the raphe neuronal terminals is a means of terminating the post¬
synaptic action of 5HT (165, 208, 377, 379) (see Introduction 1.2.7). In
the snail cerebral ganglion, imipramine enhances transmission at 5HT
synapses, aid the responses of the postsynaptic neurones increase (378,
379). The effect of 5HT on mammalian spinal reflexes is also exaggerated
by tricyclic antidepressant drugs, especially when these are used with 5HT
precursors (34, 340, 380). The responses of cerebral cortical neurones
to iontophoreticallyrapplied 5HT are potentiated by imipramine (215); the
effects of noradrenaline on brainstem and cortical neurones are similarly
potentiated, - indeed imipramine by itself may elicit the same responses
as does noradrenaline (381). Paradoxically, however, the responses of
neurones to 5HT and noradrenaline decline when high extraneuronal con¬
centrations of either monoamine are produced by large doses of imipramine-
like drugs alone or by smaller doses of these drugs in conjunction with
large doses of the monoamines (226, 381). It is premature to ascribe to
such paradoxical electropnysiological responses of tachyphylaxis (see
Introduction 1.2.7) the unexpected trend of the changes in the nucleolar
dry mass of raphe neurones in the present investigation. Nevertheless
it was of interest that both imipramine and desipramine decreased the
nucleolar parameter of raphe neurones more effectively at their lower
dosages; and that desipramine, although generally considered to inhibit
5HT uptake less than imipramine (382), still effected the more-significant
nucleolar decrement.
When desipramine was given together with reserpine, there was no
reduction in the nucleolar dry mass of raphe neurones. This finding may
have resulted from the action of reserpine in increasing the intraneuronal
breakdown of 5HT (see Discussion 3.1.4), thereby reducing the amount of
5HT released from the raphe nerve terminals; the possible importance of
the synaptic or extraneuronal pool of 5HT in regulating raphe neuronal meta¬
bolism is discussed later (Concluding Discussion 4.1).
In the present study, the nucleolar dry mass of the suprachiasmatic
neurones declined significantly only with the high dosage of desipramine.
This change might have resulted from the accumulation cf extraneuronal
5HT in the suprachiasmatic nucleus. This hypothesis is compatible with
the previous finding that, when brain 5HT was depleted by the administration
of reserpine, the nucleolar dry mass of suprachiasmatic neurones increased
(see Results 3.1.3). The concentration of extraneuronal 5HT produced by
the low doses of tricyclic antidepressants, with and without reserpine,
might have been insufficient to decrease similarly the nucleolar dry mass
of the suprachiasmatic neurones.
The arcuate nucleus contains few 5HT terminals, but rather more
noradrenergic terminals (29). Desipramine is particularly effective in
promoting the accumulation of noradrenaline outside the terminals of nor¬
adrenergic neurones (see Discussion 3.3.4.2). It was of interest, therefore,
that the nucleolar dry mass of the arcuate neurones did not alter significantly
during these experiments. As yet this finding cannot be explained convincingly.
The effects of lithium on raphe neurones include an altered
metabolism of 5HT, an enhanced uptake of 5HT into neurones, and a
reduced efflux of 5HT from neurones.
3.3.4.4 Altered 5HT metabolism: when given acutely or for up
to 5 days, lithium increases the brain content of tryptophan, 5HT and 5HIAA
(69, 383); lithium accelerates the rise in 5HT concentration after MAO
inhibition and the rise in 5HIAA concentration after probenecid (384); by
the fifth day of lithium administration, the rate of 5HT synthesis is increased
by 61482% (385). The elevation in brain 5HT and 5HIAA content after
electrical stimulation of the raphe nuclei is also greater after lithium pre-
treatment (270). However after 14 days on lithium the concentration and
turnover of 5HT in rat brain is again normal. Thereafter there is evidence
that 5HT turnover is below normal (253, 38a). One report indicates that
during the first 5 days of lithium administration, the rate of 5HT synthesis
increases only in the raphe neuronal terminals; and that subsequently me
production of 5HT is inhibited in both terminals and cell bodies (359).
3.3.4.5 Enhanced 5HT uptake: in vivo, lithium enhances the accumu¬
lation by brain tissue of isotopically-labelled 5HT given by intracisternal
injection; the isotopic labelling of the deaminated metabolites of 5HT is
also increased (202). Lithium affects similarly the uptake and metabolism
of noradrenaline (358, 387, 388). These findings indicate that, during
lithium administration, monoamines accumulating inside monoaminergic
neurones are not stored there, but are broken down quickly by cytoplasmic MAO.
3.3.4.6 Decreased release of 5HT; In vitro, lithium inhibits the
release of isotopically-labelled 5HT from brain slices during electrical
stimulation or exposure to solutions containing high concentrations of
potassium (190, 389); this inhibitory effect of lithium on monoamine
release is observed also in the brain slices of lithium-pretreated animals
(390), The release of noradrenaline from peripheral sympathetic neurones
during electrical stimulation declines similarly after lithium (391),
The increased nucleolar dry mass of raphe neurones induced try
lithium in the present study is difficult to interpret. As evidence of an
increased synthesis of ribosomes, it is consistent with the many obser¬
vations of an early, enhanced 5HT turnover in brain after lithium; but
it is less easy to reconcile with the report that tryptophan hydroxylase
activity in the cell bodies of the raphe neurones diminishes and that brain
5HT turnover decreases after 5 days of lithium. It is possible, of course,
that values for 5HT turnover and tryptophan hydroxylase activity after long-
term administration of lithium may conceal an interplay between the rate
of synthesis of "new" enzymes, and the degree of activation of "older"
enzymes concerned in forming 5HT (see Introduction 1.2.9 and Concluding
Discussion 4.1). Alternatively, other facets of raphe neuronal metabolism
involving an enhanced synthesis of ribosomes may increase after lithium.
However the spontaneous electrical activity of raphe neurones does not
alter (270), nor is there evidence that the function and synthesis of their
storage vesicles are affected. An important role for MAO in regulating
intraneuronal 5HT < olism has been suggested (146) (see Introduction
1.2.4); but although an enhanced production of MAO may have been
necessary during the early period of increased intraneuronal deamination
of 5HTf it would not have been necessary during the subsequent decline
in 5HT catabolism; moreover the inhibition of MAO by nialamide and
tranylcypromine did not alter the nucleolar metabolism of raphe neurones
(see Results 3.2.3). In dorsal-root ganglion neurones, a lithium-induced
dilatation of Golgi vesicles and increased cytoplasmic granularity have been
observed by electron microscopy; these indications of increasing neuronal
metabolism have been attributed to a lithium-provoked failure of the
membrane sodium pump of neurones (392-395). But so far, the only
major function which is directly related to 5HT metabolism in raphe
neurones and which is known to remain hyperactive during prolonged lithium
administration is the facility for 5HT accumulation; it may be significant
that, when by contrast this facility was reduced by tricyclic antidepressant
drugs, the nucleolar metabolism of raphe neurones was inhibited (see
Results 3.3.3). However no conclusions can be reached as yet about the
significance of these observations.
It is also difficult to interpret the absence of nucleolar changes in
the suprachiasmatic neurones after lithium. Ostensibly the diminished
release and enhanced recapture of 5HT by the raphe neuronal terminals
reported by other workers would tend to decrease the extraneuronal con¬
centration of 5HT in the suprachiasmatic nucleus; the inhibiti on normally
produced by 5HT there would be lessened thereby (see Introduction 1.2.7).
Possibly the effects of lithium on cholinergic metabolism and transmission
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(393-398) may have resulted in the responses of suprachiasmatic neurones
to 5HT being obscured.
3,3,5 Conclusions
The nucleolar dry mass of raphe and suprachiasiuatic neurones
decreased after tricyclic antidepressant drugs. This evidence is consistent
with other reports that these drugs depress the metabolic activity of raphe
neurones, and also promote the accumulation of 5HT outside raphe neuronal
terminals.
After lithium, only the raphe neuronal nucleolar parameter changed;
the increased dry mass was discussed in relation to the lithium-induced
chaa ges in raphe neuronal metabolism reported elsewhere.
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3,4 The effect of various monoamines, their precursors and their
analogues on the nucleolar dry mass of raphe neurones
3.4.1 Introduction
In brain tissues, the rate of 5HT synthesis may change when the
concentration of 5HT rises (see Discussion 3.2.4). A decline in brain
5HT synthesis occurs in the presence of catechol amines, phenylalanine and
p-chiorophenylalanine (PCPA)(399-404). The compound 8-hydroxydopamine
lowers the concentration of catechol amines in brain by destroying the
neurones responsible for their synthesis (405, 406).
Other monoamines found in brain include melatonin and histamine
(55, 407, 408). Many of the behavioural and endocrinological sequelae
of melatonin administration resemble those observed after giving 5HT (232,
409-412); the effects of histamine on behaviour and 5HT metabolism are
more obscure (120, 413). After bilateral cervical sympathectomy, the
rate at which melatonin is synthesized by the pineal gland is altered (408).
ft was decided to investigate the dry mass response of raphe neuronal
nucleoli to the administration of 5HT, melatonin, noradrenaline, histamine,
6-hydroxydopamine, tryptophan, PCPA and phenylalanine. Some of these
substances were given by way of the cerebral ventricles, because the pene¬
tration of brain tissue by monoamines given by peripheral routes is uncertain
(59 , 60, 74, 165, 203 , 209 , 414-417). Also Investigated were the effects on
the raphe neuronal parameter of destroying by bilateral cervical sympathectomy
the sympathetic innervation of the pineal gland and the cerebral vasculature.
FIG. 3.4.2.A. Diagram of apparatus used for infusing compounds
into the lateral cerebral ventricle of rats.
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3.4.2 Methods
3.4.2.1 Cerebral ventricular cannulation and continuous intraventricular
infusion : the principles of this technique have been described (20. 418).
£ach rat was anaesthetized with Nembutal (0.18 ml intraperitoneally);
anaesthesia was maintained with ether. The vault of the skull was exposed
by making a midline incision in the scalp. Using a 25g needle, the skull was
penetrated at a point 3 mm posterior to the right coronal suture and 3 mm
lateral to the sagittal suture. Through this aperture, the bevelled point
of a stiff, narrow-bore cannula (Fortex FP10). 70-90 cm long and containing
artificial cerebrospinal fluid (C8F), was introduced to a depth of 3mm. with
a bias towards the midline. In this position, the opening of the cannula lay
within the right lateral ventricle. The cannula was then anchored by sutures
to the adjacent pericranium. A loop of the cannula was left subcutaneously,
and then the cannula was sutured to the subcutaneous tissues. After its
emergence through the scalp incision, the cannula was threaded through a
5cm length of wide-bore polythene tubing (Portex PP325). The scalp
incision was closed by sutures around the end of this wide tube, which in
turn was held in position by further sutures. The fine cannula was supported
by a counterweight slung over a pulley, and was then connected by its free
end to a slow-infusion pump. The animal was placed in a case with an
electrified fence (Fig. 3.4.2.A.). After the rat had recovered from the
anaesthetic, it was free to move unhindered by the intraventricular cannula.
At about 2 hours after the operation, the slow-infusion pump was started.
During the following 7-9 days, this pump delivered solutions of artificial
CSF at a rate (1 jul/min) roughly half that of CSF formation (419).
Control rats received artificial CSF alone (for composition, see
Methods 3.4.2.3). Experimental rats received solution with the substances
added as described below (Methods 3.4.2.3). After 7-9 days the rats were
killed, and the nucleolar dry mass of the raphe neurones was measured.
3.4.2.2 Other operative procedures: similar preparations of raphe
nuclei were obtained from rats (see Footnote) which had either been subjected
to bilateral cervical sympathectomy 7-9 days previously, or had been given
a single injection of 6-hydroxydopamine into a lateral cerebral ventricle
(250 //g in 0.05 ml artificial CSF); animals in the latter group were killed
in batches up to 16 days after having received the injection; control animals
received a single injection of artificial CSF intraventricularly, and were
killed 10 days after.
3.4.2.3 Preparation of solutions for intraventricular infusion: a solu¬
tion of artificial CSF was prepared. Its composition was: NaCl, 121.5mM;
NaHCO'g, 25mM; KCL, 3.5mM; CaCl2, 1.3mM; MgCl 2, 1.14mM;
NaH2P04, 0.51mM; urea, 3.33mM; and glucose, 3.33mM. Using this
artificial CSF, solutions containing the following concentrations of mono¬
amines were prepared for ventricular infusion: a) low 5HT, 50 /<g/ml;
b) high 5HT, 500 fxg/ml; c) melatonin, 50yMg/ml; d) noradrenaline, 50 /<g/ml;
e) histamine, 50 //g/ml; and f) tryptophan, lmg/ml.
(Footnote: these tissues were made available by Professor W.E. Watson,
Dept. of Physiology, Edinburgh University.)
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3.4.2.4 Preparations of substances for intraperitoneal injection:
tryptophan was partly dissolved and partly suspended in Ringer lactate at
a concentration of 50mg/ml. The fluid was warmed to skin temperature
and slightly acidified (2 drops of N hydrochloric acid delivered by Pasteur
pipette into 5 ml tryptophan-fluid), in order to enhance the solubility of
tryptophan. Control solution was prepared from which only the tryptophan
Iml
was omitted. Each rat was given daily either^tryptophan fluid or control
solution by intraperitoneal injection. The nucleolar dry mass of the raphe
neurones was measured on day 8.
Fluid containing phenylalanine was prepared similarly, at a concen¬
tration of 100 mg/ml. Each rat was given 100 mg of phenylalanine daily
by the intraperitoneal route. Control animals received aliquots of control
solution prepared as for the tryptophan experiment. These rats were also
killed after 8 days, and the raphe neurones were studied as above.
PLPA (at p. concentration of 60 mg/ml) was suspended in saline
containing 1% Tween 80. In one group of rats, each animal received 1 ml
of this fluid daily for 8-9 days by intraperitoneal injection. In a second
group, each rat received the same injections of PCPA fluid on alternate
days, but on every second day received 50 mg nialamide in 1 ml saline by
intraperitoneal injection. In a third group of rats, each animal received
daily injections of 1 ml control solution, which consisted of 1% Tween-
saline solution. All rats were killed between days 8 and 10. The nucleolar





Fig. 3.4.3.A. Raphe neurones: columns Indicate pooled mean nucleolar dry
mass, with standard errors, grouped according to experimental




Fig. 3.4.3.B. Raphe neurones: data presented as above, but rats were given
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The nucleolar dry mass of raphe neurones was reduced by the
continuous intraventricular infusion of "low-5HT" and of melatonin.
No changes were seen after similarly infusing ' high-5HT", noradrenaline,
. ' i
histamine or tryptophan. The procedures involving 6~hydroxydopamine
injection and cervical sympathectomy were also without effect (Figs.
3.4.3.A. & B.).
After daily intraperitoneal injections of tryptophan for 8 days, the
nucleolar dry mass of the raphe neurones decreased (Fig. 3.4.3.C.).
After intraperitoneal phenylalanine for 8 days, the same parameter tended
to Increase, but the difference was not statistically significant (Fig,
3.4.3.D.). After PCPA alone, the same parameter also tended to
increase at day8-10, although again the increase was not significant} when
PCPA wasgiven with nialamide, this tendency to increase was not observed
(Fig. 3.4.3.E.).
The rats in some experimental groups displayed distinctive patterns
of behaviour. Two days after the onset of intraventricular infusion with
"low-5HT" or with melatonin, rats became very drowsy, and showed a
reduction both in spontaneous motor activity and in reactivity to simple
tactile and auditory stimuli; the animals remained thus throughout the
experiment. With the infusion of "high-5HT", the rats became drowsy
within minutes; but after day 1, they became hyperactive and hyperreactive;
while at rest they display 1 a spreadeagled stance, tail dorsiflexion, and a
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coarse tremor and titubation. Rats receiving noradrenaline or tryptophan
in the intraventricular infusate also were more excitable, - moving around
within their cages frequently and also reacting sharply to stimuli; these
signs started on day 2, but were not preceded by drowsiness. For 1 hour
after the single intraventricular injection of 6-hyaroxydoparaine, the rats
were hyperactive and hyperreactive; a subsequent 12-hour phase of extreme
immobility and unresponsiveness disappeared gradually, and behavioural
normality returned during day 2. Those rats with cervical sympathectomy,
and those receiving intraventricular histamine solution, artificial CSF alone,
and the intraperitoneal injections appeared normal.
Two rats were discarded from both the noradrenaline and the
tryptophan groups because of their poor condition. Apart from them, the
general condition of all rats was good, and their intake of food and water
was maintained.
During those experiments involving continuous ventricular infusion,
the hyperactivity associated with tryptophan and noradrenaline caused
coiling of the intraventricular cannulae. Despite frequent sessions
devoted to reversing this process, cannulae occasionally became kinked,
and the infusions therefore may have been intermittently obstructed. As
a result the rate of administration of sub&i mces during these experiments
may have been slightly less than the stated value.
65
3.4.4 Discussion
5HT given into the cerebral ventricles is taken up at low concen¬
trations by the raphe neurones only (165, 210); at higher concentrations
5HT is also accumulated by catecholamine-containing neurones (205, 207,
208, 248, 420, 421) and other cells (209, 420, 422). The progressive
rise of endogenous 5HT concentration in brain tissues after MAO inhibition
is sometime s accompanied by a fall in the rate of 5HT formation from
tryptophan, -but not from 5HTP (237, 280-282, 336, 342); when present,
this inhibition of 5HT synthesis may result from alterations in the degree
of end-product inhibition of tryptophan hydroxylase by 5HT. A similar
mechanism contributes to the regulation of brain noradrenaline synthesis
(see Introduction 1.2.9). 5HT inhibits many aspects of brain metabolism,
including glycolysis (423) and the synthesis of ribonucleic acid and protein
(424-426). As yet, no 5HT-containing nerve terminals have been demon¬
strated in the raphe nuclei (23, 29, 427). But when 5HT is introduced by
iontophoresis into the raphe nuclei, the firing of most of these neurones is
inhibited (428), although some neurones are excited (213, 427); in the
dorsal raphe nucleus, which is composed almost exclusively of 5HT-
containing neurones (24) only the inhibitory responses to 5HT are evoked
(327). In the present study, the decreased nucleolar dry mass of raphe
neurones indicates that when these neurones are exposed chronically to
exogenous 5HT, their production of ribosomes is inhibited; but that this
inhibition ceases to operate during exposure to high concentrations of
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exogenous 5HT. These results may be an Indirect result of the non¬
specific uptake of 5HT at high concentrations (see above), or may be related
to events at the postsynaptic receptors for 5HT. These results will be
discussed later (see Concluding Discussion 4.1).
Melatonin may be present in the hypothalamus (55). In vitro the
cerebral cortex accumulates isotopically^labelled melatonin (429).
Melatonin increases the synthesis of 5FT in brain extracts; when given
systemically, it raises the 5HT content of brain (430), possibly by
increasing the availability of a cofactor necessary for 5HT synthesis (431).
In the present study, however, melatonin infusion, like low-5HT infusion,
diminished the nucleolar dry mass of raphe neurones. An interpretation
of these findings will be given later (see Concluding Discussion 4.1).
Histamine is present in the central nervous system (407, 432). Its
turnover increases after reserpine (433). In the present study, histamine
infused into the cerebral ventricles was without effect on the nucleolar dry
mass of raphe neurones.
The pineal gland is richly innervated by sympathetic nerve terminals;
it also contains 5HT and melatonin, and the enzymes which synthesize and
break down these compounds. After cervical sympathectomy, various
aspects of the metabolism of 5HT and melatonin are altered (408). In the
present study, the absence of any change in the nucleolar dry mass of
raphe neurones showed that this procedure did not affect their synthesis
of ribosomes.
The drug 6-hydroxydopamine causes the degeneration of noradrenergic
neurones, and the brain content of noradrenaline falls rapidly in consequence
(405, 434-442). However the activity of enzymes synthesizing 5HT in
brainstem tissue does not alter (406, 443), nor does the rate of conversion
in vitro of isotopicaliy-labelled tryptophan into 5HIAA (444). There are
other indications that raphe neuronal function is not significantly affected
by 6-hyriroxydopamine (35 , 248, 435, 436, 445-443). This view is supported
by the unchanged nucleolar dry mass of raphe neurones observed in the
present study.
Many changes in 5HT metabolism have been reported to follow the
administration of catechol amines and their precursors (404, 448-451).
Some of these metabolic interactions have been attributed to local competition
for enzymes and cofactors (240, 279 , 452-460), for transport mechanisms
(71, 118, 177, 224, 446) and for amine storage sites (446, 454, 462-464).
Phenylalanine can be considered as example: rats fed on a high-phenylalanine
diet for 7-12 days show a reduced 5HT concentration and a low rate of 5HT
synthesis in brain tissue (401, 402); in vitro. the uptake of isotopically-
labelled tryptophan by cerebral cortical slices and by whole brain synapto-
somes diminishes in the presence of phenylalanine, and the efflux of
tryptophan from these synaptosomes accelerates (63, 65); in addition,
phenylalanine inhibits tryptophan hydroxylase (37, 404). Noradrenergic
terminals are present in the raphe nuclei; there are many in the dorsal
raphe nucleus, but few in the median raphe nucleus (29). Iontophoratically-
applied noradrenaline increases or diminishes the spontaneous electrical
activity of neurones in the raphe nuclei (427). In the present study, however,
while the intraventricular infusion of noradrenaline produced striking
behavioural changes, there were no alterations in the nucleolar dry mass
of raphe neurones. After parenteral phenylalanine, the same parameter
increased, but the change was not statistically significant.
The effect of parenterally-administered tryptophan on 5HT metabolism
in brain is not clear. Diets rich in tryptophan increase brain 5HT content
(402), while the converse result is produced by txyptophan-poor diets (324,
465). Nevertheless the regulation of the uptake by brain tissues of plasma
tryptophan is not fully understood (66, 81, 466, 467), although the degree of
tryptophan-binding by plasma proteins is important (67, 468, 460).
Tryptophan given by parenteral or intracerebral injection initially
increases 5HT synthesis and elevates the brain concentration of 5HT and
5H1AA (68, 81, 470-473). After an intraperitoneal injection of tryptophan
(IGOmg/kg), 5HT fluorescence in raphe tissue of the rat increases (264).
But above a certain dosage of tryptophan, which differs in various studies,
progressively increasing the amount of tryptophan results in only the 5H1AA
continuing to rise; very high doses of tryptophan only prolong the plateau-
levels of both 5HT and 5H1AA (78, 111). Hence the evidence indicates
that the increased amount of tryptophan available to brain tissues is taken
up by raphe neurones and converted into 5HT (474) (see Introduction 1.2.3);
and that when the vesicle-stores for 5HT are filled, excess 5HT is catabo-
lized by MAC (176, 472, 475). It has also been suggested that more 5HT
may be released from the raphe neuronal terminals on to postsynaptic
receptors (201, 476-478). But there is no evidence that the administration
of tryptophan induces the production of more 5HT-Sj nthesizing enzymes
and MAO in the raphe neurones. Indeed the reduction in raphe neuronal
electrical activity after tryptophan may indicate that their functional
activity is inhibited (264, 478). This hypothesis is compatible with the
decreased nucleolar dry mass demonstrated in the r-rr :ent study after
intraperitoneal injections of tryptophan; this finding is discussed later
(see Concluding Discussion 4.1). Unexpectedly, however, the intraventri¬
cular infusion of tryptophan produced no change in the raphe neuronal para¬
meter. It is possible that the membrane uptake by raphe neuronal cell
bodies and terminals of the tryptophan given by these two routes may
have differed because of the concurrent uptake of this amino acid into
dissimilar populations of other neurones and of glial, ependymal and
endothelial cells (66, 99 , 208, 240, 456, 461, 466, 474, 479-481). Dis¬
crepant effects on the synthesis-rate of 5HT in raphe neurones might have
arisen from such different characteristics in the two routes of administration,
or from the different dosages of tryptophan provided in these two experi¬
ments (see Introduction 1.2.3). However the tryptophan concentration
and 5HT turnover in rat brain were not measured in this study; hence
there is no basis for comparing the dissimilar values for the raphe neuronal
parameter after tryptophan with those found after the intraventricular
infusion of low and high concentrations of 5HT (Results 3.4.3).
After the administration of PCFA, the concentration of 5HT and
5HIAA declines slowly (482) to values dependent on the size and frequency
of the dosage <399 , 483-485). A reduced turnover of 5HT is also demon¬
strated by the low concentration of 5HIAA in C8F (486), and by the slow
rise of this concentration after probenecid (487). After PCPA, the rate
of conversion of isotopicaily-labelled tryptophan into 5HXAA by midbrain
tissue in vitro declines (444), and the accumulation of isotopically-labelled
5HT from 3H-tryptophan is retarded (488); however the retention of 3H-5HT
in mouse brain is unchanged (488), or even increased (489). These
reports suggest that PCFA does not increase the rate of breakdown or
elimination of 5HT but rather inhibits some steps in its synthesis.
PCPA decreases the transport of many amino acids into brain (490).
In synaptosomes prepared from rat brain, the uptake of isotopically-
labelled tryptophan decreases while the tryptophan efflux increases (65).
In vivo the tryptophan concentration in rat brain is low after 3 days of PCPA
treatment (383); however, in the 5MT-containing neurones of the snail, 14C-
tryptophan uptake does not alter after PCPA, although the 5HTP synthesized
from it is reduced (80). In rat brain homogenate, PCPA also inhibits the
conversion of 14C-tryptophan into 5HT (404); although in vitro this PCPA-
induced inhibition of tryptophan hydroxylase appears to be mainly competi¬
tive, in vivo most of the inhibition is irreversible, and appears only after
a 2-day timelag (491). One deduction from this finding is that delayed
inhibition is caused not by PCPA itself, but by some metabolite of PCPA
(49? -494). An alternative proposal is that the delayed inhibition results
from th nthesis of defective tryptophan hydroxylase enzymes (493);
this may arise from PCPA being incorporated at the active sites of these
enzymes as they are formed in the cell bodies of the raphe neurones (236,
495); as a result, the main inhibitory effects become apparent only as
the defective enzymes reach the raphe neuronal erminals (91, 496, 497),
where most 5HT is synthesized (see Introduction 1.2.3). However it is
difficult to reconcile this view of PCPA-induced inhibition with other findings:
for example, when the axonal transport of newly-synthesized enzymes from
the cell bodies of the raphe neurones to their terminals is stopped by
destroying the cell bodies themselves (498) or by transecting their axons
(499), PCPA still inhibits the formation of 5HT by tryptophan hydroxylase
already present in their terminals; however it may be rash to presume
that 5HT-synthesizing enzymes cannot be produced in the terminals (see
Introduction 1.2.3).
Whatever the mechanisms involved, PCPA-induced inhibition of
5HT synthesis is only partial (400, 482). For instance, in raphe neurones
the intensity of 5HT histofluorescence produced by giving tryptophan may not
alter after PCPA pretreatment (264); this finding has been challenged
recently, however (500). After PCPA the amount of isotopically-labelled
5HT formed in brain from radioactive tryptophan is unaltered, both under
basal conditions and when median raphe neurones are stimulated electrically
(259, 400); in intact animals subjected to mild stress, 5HT synthesis may
even increase despite the presence of PCPA (347). The incompleteness of
the inhibition of 5HT synthesis may result from an increased activity of
extant enzyme (91, 259) or it may reflect the capacity of raphe neurones
to synthesize more enzyme than can be inactivated by PCPA*
The uncertainty about how PCPA inhibits 5HT synthesis in raphe
neurones makes more difficult the interpretation of the findings of the
present study. These findings were that PCPA alone tended to increase
the nucleolar dry mass in raphe neurones; but that when PCPA and the MAO
inhibitor nialamide were given on alternate days, there was no such tendency.
It is of interest, however, that the nucleolar responses of raphe neurones to
the dec^ae in brain 5HT content caused by PCPA, phenylalanine and reser-
pine were qualitatively similar.
Sedation has been reported to accompany the intraperitoneal (501)
or intraventricular administration of 5HT (232, 323), the intravenous or
intracerebral injection of melatonin (410, 412), and the low-frequency stimu¬
lation of the raphe neurones (196). Behavioural excitation follows large
doses of 5HT given intraventricularly (502), the administration of tryptophan
or 5HTP with nialamide (470, 473, 503-506), nialamide with tricyclic
antidepressant drugs (507), and high-frequency electrical stimulation of the
raphe nuclei (198). In the present experiments the intraventricular infusion
of low-dose 5HT and of melatonin induced sedation; with high-dose 5HT
infusion, sedation wag soon followed by agitation; with noradrenaline and
tryptophan infusion, only behavioural excitation was seen. Hence only those
intraventricular infusions which induced continuous sedation in the experimental
animals were accompanied by decrements in the nucleolar dry mass of raphe
73.
neurones. PCPA Is reported to alter the behaviour of rats (see Discussion
3.6.4.3); in the present experiments, where only gross behavioural
changes were observed and recorded, behavioural abnormalities were not
seen.
3.4.5 Conclusions
Low doses of 5HT and melatonin given by intraventricular infusion
for several days decreased the nucleolar dry mass of raphe neurones.
No such change was seen after the intraventricular infusion of high-dose
5HT, tryptophan, noradrenaline, histamine and 6-hydroxydopamine or
after cervical sympathectomy. Of the substances given intraperitoneal^,




3.5 The effect of some other drugs on the nucleolar dry mass of raphe
neurones
3.5.1 Introduction
The drugs which were given to rats in the experiments already
described produce psychological changes in humans. MAO inhibitors,
tricyclic antidepressants, oxypertine and lithium are effective in various
psychiatric syndromes, while reserpine also has psychological effects
(356, 357, 508-511). The involvement in 5HT metabolism of many other
psychotropic drugs is still obscure.
it was decided to investigate the effects on the nucleolar dry mass
of raphe and various hypothalamic neurones of two such drugs, diamorphine
and barbitone.
Changes in the turnover of 5HT have been reported during the
administration of morphine (512, 513). The production of opiate analgesia,
tolerance and dependence may involve brain 5HT metabolism (442, 514-520).
The phenomenon of dependence is also found after barbiturate
therapy, and barbiturates are well-known for their hypnogenic properties
(521); these properties are attributed also to 5HT una melatonin (482, 484,
501, 504, 522, 523). Barbiturates may influence 5ET metabolism (524).
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3.5.2 Methods
In the diamorphine experiment, each rat was given intraperitoneal
injections of lmg diamorphine twice daily, at 10.00 hrs. and at 16.00 hrg.
Control animals received similar injections of Ringer lactate solution.
Animals from experimental and control groups were killed during the
following 18 days of the experiment. Nucleolar dry mass measurements
were made on raphe neurones and on neurones from the suprachiasmatic,
arcuate, ventromedial and dorsomedial nuclei of the hypothalamus. These
nuclei were obtained as described earlier (General Methods 2.2). The
control animals were killed cn days 4, 8, 10, 14 and 17; because the
nucleolar values obtained from each animal did not change throughout the
experiment, the results were pooled as a single control value.
Three experiments were conducted in which barbitone sodium was
added to drinking water at an initial concentration of 4 grn/L. In the first
experiment, rats were caged individually and were allowed free access only
totiis drinking solution; an activity wheel was attached to each cage. At
days 10 and 17, the concentration of barbitone was raised to 8 gm/L and
10 gm/L respectively. Control animals were similarly caged, but
received ordinary water to drink. The food and water intake of each rat
was measured daily during the 37 days of the experiment. The reading
on the counter of each activity wheel was noted daily, and each rat was
weighed every second day.
In the second experiment, drinking-water containing barbitone
(4gm/L) was provided for rats grouped normally, 6 to a cage. At
days 11, 14, and 83, the barbitone solution was replaced by ordinary
drinking water in some cages. The other rats continued to drink the harbi-
tone water for up to 23 days. Hats were killed at various times after
barbitone-drinking hac oeen started, and also for some days after it had
been stopped. Control animals received ordinary drinaing water; they
were killed in batches at the beginning and end of the experiment.
In the third experiment, 4-month-old rats were housed normally
and were given drinxing water with the barbitone concentration maintained
at 4grn/L for up to 29 days. Eats drinking ordinary water acted as controls.
At days 27 and 29 of the experiment, the rats receiving the drug were
killed. Control rats were killed on aay 28.
While in all rats the nucleoli of raphe neurones were examined,








Fig. 3.5.A. Various neurones: columns indicate pooled mean nucleolar
dry mass, with standard errors, for groups of rats; experimental
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ARCUATE DORSOME DIAL VENTROMED.
Fig. 3.5.B. Various neurones: data presented as in Fig. 3.5.A.
RAPHE SUPRACHIASM. ARCUATE
Fig. 3.5.C. Various neurones: data presented as in Fig. 3.5.A., but
experimental animals received increasing doses of barbiturate
orally for 37 days.
RAPHE BARBITONE + WITHDRAWAL
Fig. 3.5.D. Raphe neurones: data presented as in Fig. 3.5.A., but
barbiturate was given orally, and then withdrawn at different
stages during the experiment.
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Fig. 3.5.E. Arcuate and suprachiasmatic neurones: data presented as
in Fig. 3.5.A., but experimental animals received barbiturate







Fig. 3.5.F. Various neurones: data presented as in Fig. 3.5.A. but
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0.41165 0.27208<0.001 0.295 0.2459N.S.(0 -0.1) 0.2940 0.275N.S.
3.5.3 Results
Between days 5 and 9 of the dlamorphine experiment, the nucleolar
dry mass of raphe neurones declined slightly, but not significantly. There
followed a transient but significant increase in the same parameter at days
11-12 (Fig. 3.5.A.). In the supracuiasmatic neurones, the nucleolar dry
mass also increased, but later than in the raphe neurones (Fig. 3.5.A.).
No significant changes were seen in the nucleolar dry mass of the other
neurones examined (Fig. 3.5.B., Table 3.5).
With barbitone (Figs. 3.5.C. & F., Table 3.5.), the raphe neuronal
parameter was not decreased at day 5. But by day 14, a highly-significant
decrease was apparent; this decrease was maintained for 30 days. The
changes in dry mass values were dose-related. After withdrawing the
drug at days 11, 14 and 23, the nucleolar parameter returned to normal
within 7 days in each case; there was no "overshoot".
For the nucleoli of arcuate and suprachiasmatic neurones, the dry
mass values decreased during barbiturate administration. The dry mass
decrements of the arcuate neurones were greater than those of the supra¬
chiasmatic neurones, in which a significant change was seen only in rats
receiving barbiturate for 37 days.
In the early stages of the dlamcrphine experiment, there was evidence
of drug toxicity: one rat was found dead on each of the first four days; and
during the early experimental period, the other rats were lethargic and ate
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less food. But after this initial period, the condition of all rats improved.
During the barbiturate experiments, the rats became tranquil, and
responded lethargically to auditory and tactile stimuli. They appeared
healthy, in that there was no soiling or eye-crusting. In the first of these
experiments, rats were caged individually in order to monitor more closely
their behaviour during the experimental period: the daily intake of food and
water remained constant; during the first 2-3 weeks of the experiment,
the weight of each animal rose by approximately 20-35 gm, but by the end
of the experiment the starting values for weight were regained; lastly,
although the animals were drowsy, lethargic and moderately unresponsive
to stimuli when observed during daytime, the readings on the counters of
the activity wheels attached to each cage provided evidence that during the
nocturnal periods, normal activity was maintained throughout the experi¬
mental period.
3.5.4 Discussion
After morphine, brain 5HT concentration is usually unchanged (383,
512, 525), although it is reported to be low in one instance (526). The
effect of morphine on the turnover of 5HT is more controversial (527).
During tnc administration of morphine, the 5HT turnover in rat brain is
raised at 3 days and at 3 weeks (513). During morphine dependence, the
regional turnover of 5HT is elevated in brainstem and hypothalamus more
than in other brain areas (518); yet conflicting results are reported (528).
In other experiments, 5HT turnover rises within a few hours of the admini¬
stration of morphine both in rat brain (512, 529) and in mouse brain (530,
531); but is reported to be unchanged at day 3 (532) and at day 4 (533, 534)
in mouse brain, and at day 5 (535) and days 6-9 (536) in rat brain.
This conflict of evidence about 5HT metabolism may have several
origins. Firstly, different dosage schedules may produce discordant
results (536, 537), and the pharmacological effects of morphine given as
pellet implants or by injection may also differ. Secondly, the values for
5HT turnover after morphine in mouse experiments depend on the strain of
mouse used (538); the same variability may exist in rats. Thirdly, in vitro
MAO is partially inhibited by morphine (539); in vivo , morphine withdrawal
is followed by an increased MAO activity (540). Hence in morphine experi¬
ments, when 5HT turnover is deduced by using MAO inhibition (see
Introduction 1.2.8), the results may be inaccurate.
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When given intravenously, morphine does not inhibit the spontaneous
firing of dorsal raphe neurones, although the firing of central noradrenergic
neurones is depressed (541). Nor, when given by micro-iontophoresis,
does morphine induce electrical responses in brainstem neurones which
can be correlated with their responses to 5HT (542).
In the present study, the nucleolar dry mass of raphe and supra-
eMasmatic neurones was increased by diamorphine; these increments had
a slower onset than the otherwise similar Increases observed after reserpine
(see Results 3.1.3). In the ventromedial neurones, too, the decline in the
nucleolar dry mass values resembled the change seen after reserpine,
Ventromedial neurones may be selectively involved in the development of
morphine-dependence and tolerance (543, 544).
Opiates have protean effects on brain metabolism (545-553). Until
further details are known about these effects, the interpretation of the
nucleolar changes in the present investigation will remain difficult. Never¬
theless the present results show an increased ribosomal synthesis in raphe
and suprachiasmatic neurones; this finding is consistent with the reports
of enhanced 5HT turnover in brain after morphine.
The concentration of brain 5HT declines within minutes of an intra¬
ventricular injection of barbiturate (554). Howewr, between 30 minutes and
24 hours after the parenteral administration of barbiturate, brain 5HT
concentration rises (333, 524, 555, 556). The turnover of 5HT. in brain
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is low 3 hours after the administration of barbiturate, although at this time
the 5HT concentration in brain is normal (557, 558). Barbiturates given
parenterally or by iontophoresis depress the electrical activity of most
neurones in the central nervous system (217, 559, 560). Barbiturates
also alter the transmitter actions of 5HT: the excitatory responses of
various neurones to 5H1 are inkibiteo (216), while the inhibitory effects
of 5HT on other neurones may become more pronounced (218). An inter¬
action between barbiturates and 5HT metabolism has been demonstrated
during the induction and maintenance of sleep (561, 562), and in the inhibition
of convulsions (563-566). Other findings indicate that barbiturates
inhibit many facets of neuronal metabolism: these include noradrenaline
turnover (567), acetylcholine release (568), glycolysis and oxygen utilization
(569,570).
This view of a general depression of neuronal metabolic activity is
consistent with the findings in the present study, - that the nucleolar dry
mass is reduced not only in raphe neurones, but also in arcuate and (less
markedly) in suprachiasmatic neurones.
3.5.5 Conclusions
Two psychotropic drugs were given to rats. Diamorphine induced a
delayed increase in the nucleolar dry mass of both raphe and suprachiasmatic
neurones; the change in the raphe neuronal parameter preceded that in the
suprachiasmatic neurones. Barbitone decreased the nucleolar dry mass of
raphe, arcuate and suprachlasmatic neurones; the change in the raphe
neurones was the most pronounced, while that in the suprachiasmatlc
neurones was least marked. These findings were discussed in relation to
the other actions of these drugs on brain 5HT metabolism.
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3.6 The effect ou raphe neuronal dry mass of some procedures which
may alter the tissue levels of various steroid hormones
3.6.1 Introduction
Increased and decreased amounts of steroid hormones might influence
the nucleolar dry mass of raphe neurones. Some of the following experiments
were preliminary, and designed to observe the effect of several procedures
while using relatively few animals.
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3.6.2 Methods
Several experiments were performed.
Experiment I: (a) cortisone acetate (12.5mg) was given to each rat by
intraperitoneal injection, daily for 14 days; (b) testosterone propionate
(25mg) was given to each rat subcutaneously daily for 6 days; (c) each
control animal was injected intraperitoneally with almond oil (0.5ml daily)
for 8 days. When the series of injections were complete, the animals were
killed and the nucleolar dry mass of raphe neurones was measured.
Experiment II: testosterone propionate (O.Smg) was injected subcutaneously
into each rat on alternate days for 12-14 days. Uninjected animals were
used as controls. Again the nucleolar dry mass of their raphe neurones was
measured; in some animals the nucleolar dry mass of suprachiasmatic
neurones was measured.
Experiment HI: (a) Eats were subjected to bilateral adrenalectomy. Under
ether anaesthesia,, bilateral skin incisions were made in the dorso-lumbar
regions of the rat, directly inferior to the rib cage and lateral to the lumbar
musculature. After further deep dissection, the adrenal glands were
identified in relation to the psoas muscle; the periadrenal fat was displaced,
and the glands avulsed. There was little blood loss. Saline (2ml, 0.9%)
was infiltrated subcutaneously before the wound was closed. Silk sutures
were used for closing muscle and skin incisions.
Some of these animals subsequently received daily subcutaneous
injections of cortisone acetate (12.5mg each) for up to the tenth day
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postoperatively, when they were killed; the cortisone impaired wound
healing in these rats, and from day 6 onwards the wounds of some animals
began to gape. The wounds of the rats not receiving cortisone healed
normally, and those animals were killed between days 8 and 12 postoperatively.
Control rats were sham-operated; the only difference in procedure was
that the adrenal glands were left intact; postoperatively the condition of
these animals was normal. All rats were allowed free access to normal
and 0.9% saline drinking water.
Experiment III: (b) At a later date, midbrain tissues containing raphe
neurones were obtained from rats which had been subjected to adrenalectomy
12-15 days previously (see Footnote). Unoperated animals were used as
controls. The nucleolar dry mass of the raphe neurones from both groups
of animals was compared.
(Footnote: these tissues were obtained from animals provided by
Professor W.E. Watson.)
Fig. 3.6.A. Raphe neurones: columns indicate pooled mean nucleolar dry
mass, with standard error, of groups of rats; the rats were
injected with cortisone for 14 days or with a high-dose of
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Fig. 3.6.B. Raphe and suprachlasmatic neurones: data represented as in
Fig. 3.6.A., but experimental animals received a low-dose of
testosterone by injection for 12-14 days.
RAPHE SUPRACHI ASH. ARCUATE
Fig* 3.6.C. Various neurones: data represented as for Fig. 3.6.A., but
experimental rats were subjected to adrenalectomy (d 8*12);
























Fig. 3.6„D. Raphe neurones: data presented as in Fig. 3.6.A., but animals










































































































There were significant increases in the raphe neuronal nucleolar
dxy mass after repeated injections of testosterone, but not after cortisone
(Figs. 3.6.A. &B., Table 3.6.). The increments after testosterone were
dose-related.
After testosterone the nucleolar dry mass of suprachiasmatic neurones
decreased (Fig. 3.6.B.).
After adrenalectomy there were no significant changes in the
nucleolar dry mass of raphe neurones of rats killed at days 8-12 or 12-15
(Figs. 3.6.C. & I)., Table 3.6.), In the former series, when adrenalecto-
mized rats received cortisone injections daily, the nucleolar parameter of
raphe neurones still did not alter. The nucleolar dry mass of arcuate and
suprachiasmatic neurones was also unaffected by adrenalectomy in these
experiments (Fig. 3.6.C.).
3.6.4 Discussion
3.6.4.1 Corticosteroid injections: in several studies a biphaaic
effect of corticosteroids on brain 5HT content has been observed. The 5HT
and 5H1AA contents of rat brain decrease directly after the systemic injection
of hydrocortisone (254, 571); but following the repeated injection of cortico¬
steroids during 5 days, brain 5HT content is reported normal (572); and
after very large doses of these drugs given for 20 days, brain 5HT content
increases (333, 571). The capacity for 5HTP decarboxylation in brain does
not change either after 5 days of corticosteroid injections or after adrenalectomy
(572). Corticosteroids may reduce the synthesis of 5HT initially by an indirect
mechanism: they stimulate the activity of hepatic tryptophan pyrrolase, which
facilitates the conversion of piasma tryptophan to kynurenine (42) (see
Introduction, Fig. 1.2.2.); kynurenine inhibits the uptake of tryptophan by
brain tissue, and the synthesis of 5HT declines (40, 41, 572). However this
mechanism does not account for the subsequent increase in brain 5HT content
(571).
The rate of conversion of isotopically-labelled tryptophan into 5HIAA
by midbrain explants from rats can be measured in vitro. thereby eliminating
the effects of hepatic tryptophan pyrrolase activity: in these circumstances,
the turnover of 5HT remains unchanged during 18 days exposure to cortico¬
steroids (444).
In the present study, the nucleolar dry mass of the raphe neurones was
unaltered at day 14. This observation reinforces the opinion that the changes
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in brain 5HT content after the administration of corticosteroids may result,
for example, from alterations in the accessibility of tryptophan to the 5HT-
synthesizing enzymes in brain; changes in the production of these synthetic
enzymes and in their intracellular concentration in the raphe neurones may
not be involved (see Concluding Discussion 4.1).
3.6.4.2 Adrenalectomy: between 5 and 10 days after adrenalectomy,
tryptophan hydroxylase activity declines in the brainstem but not in the
tfclediencephaion, while in both regions the content of tryptophan and 5HT
remains constant (573). This regional decline in tryptophan hydroxylase
activity is accelerated by cyclcheximide, but is partly counteracted by
injections of corticosteroids (574). However, the precise effects of
adrenalectomy on the mechanisms involved in tryptophan hydroxylase
biosynthesis remain unclear. 2n the present studies, there were no
changes in the nucleolar dry mass of raphe neurones from 8 to 15 days after
adrenalectomy, or when corticosteroids were injected into adrenalectomized
rats for 14 days.
Elsewhere, increases in the nucleolar dry mass of various hypo-
thalamic neurones have been reported after adrenalectomy (21). These
Increases appear very early after the operation; and in some neurones
they persist until day 11 post-operatively, while in other neurones they
have disappeared by the fifth day. In the present study on raphe neurones,
the observations were made only between days 8 and 15 postoperatively.
Hence it would be necessary to investigate the response of raphe neuronal
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nucleoli during the first seven days after adrenalecomy before concluding
that adrenalectomy did not affect the dry mass of raphe neuronal nucleoli.
3.6.4.3 Testosterone injections; there is some controversy about
a possible relationship between 5HT metabolism and sexual behaviour.
When MAO is inhibited, the 5HT content of rat brain rises while the sexual
activity of the rats declines; PCPA reverses the biochemical and behavioural
effects of MAO inhibition: when 5HTP is given with PCPA and MAO inhibitors,
however, the original effects are reproduced (575, 573). Again, when the
5HT content of rat brain is lowered by the administration of L-DOPA or
5-6 dihydroxytryptamine, the sexual behaviour of the rats increases; a
subsequent injection of 5HTP abolishes this activity (577, 578). The
administration of 5HTP also abolishes the decline in brain 5HT levels
and the increase in sexual activity brought about by PCPA alone (579, 580).
According to one report, however, PCPA has little effect on sexual activity
of cats although it reduces their brain 5HT content (581). Nevertheless in
most experimental animals, an inverse relationship is observed between
brain 5HT levels and the degree of sexual activity displayed by the animals.
There is some confusion as to whether this 5HT effect on sexual
behaviour is mediated in some way by endogenous testosterone. Methodo¬
logical differences in the procedures of the various experiments - age of
rat, type of housing, dosage of drug and hormone, and type of sexual, social
behaviour measured - may underlie the discrepancies in the findings (575-
583).
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The findings in the present study of the nucleolar dry mass of
various neurones after the administration of testosterone were of
interest, in that they confirmed a relationship between 5HT metabolism
and testosterone: testosterone (at the high dose) increased the nucleolar
dry mass of raphe neurones (see Results 3.6.3.); with PCPA a similar
change was seen, although it was not statistically significant (see Results
3.4.3.). By contrast, the nucleolar dry mass of the suprachiasmatic
neurones decreased; this observation was of interest because of the report
that, after castration, the nucleolar dry mass of these neurones increases
(21). The mechanisms which link the metabolic responses in these two groi^ps
of neurones - if indeed they are linked - remain obscure.
3.6.5 Conclusions
In these preliminary experiments, adrenalectomy and corticosteroid
injections, alone or together, had no effect on the nucleolar dry mass of
raphe neurones. After testosterone injections, the nucleolar parameter
of raphe neurones increased while that of suprachiastriatic neurones
decreased. These changes were discussed in relation to other changes in
brain 5HT metabolism following these procedures.
Some of these experiments were preliminary, - designed to evaluate
profitable lines of investigation into steroid-5HT interactions hence




Many of the compounds used in the experiments described in this
thesis have been shown by workers using other techniques to affect the
metabolism of 5HT in brain; 5HT concentration, turnover or subcellular
distribution may be altered. One of the aims of the present study was to
identify possible relationships between changes in these indices of raphe
neuronal metabolism and the alterations in nucleolar dry mass described
in this thesis. In doing so, several problems had to be faced.
Firstly, the proportion of 5HT-containing neurones within the "median
raphe nucleus" block of tissue excised is uncertain. At present there
appears to be no technique by which this problem can be resolved with
certainty. On examining preparations of raphe tissue by interference micro¬
scopy, a heterogeneity in neuronal and nuclear size was apparent; the dry
mass values of the individual neuronal nucleoli were also variable. When
the technique of formaldehyde histofluorescence is used (see Introduction
1.2.2), the faint yellow fluorescence, which is held to denote the presence of
5HT, is observed in most of the raphe neuronal bodies. Yet the disadvantages
of this technique are, firstly, that small amounts of intracellular 5HT may
not be detectable (25 , 27, 584-587); secondly, that similar fluorescence
may be produced by indoles other than 5HT (38, 242, 341, 588). In electro¬
physiological studies, when recording electrodes are placed in the median
and dorsal raphe nuclei, many of these neurones - especially those in the
95.
dorsal raphe nucleus - display slow(2 per second) firing rates: these
neurones are thought to be 5HT-containing neuroner, because drugs which
alter 5HT metabolism also change the firing rate of these neurones, but do
not affect neurones in adjacent regions of the brainstem (258, 264, 360, 377).
Thus the indications are that most neurones within the median raphe nucleus
contain 5HT, although the precise proportion is not known (23, 24, 589).
Secondly, many of the drugs used in these experiments have protean
effects on brain metabolism, as well as effects on 5HT metabolism. Some
of these effects are indicated below:
BRAIN METABOLISM AFFECTED : References
Drug Catechol amines Acetylcholine Other
Reserpine 126, 255, 330 332-334, 599
MAO inhibitors 239, 339, 346, 590
tricyclic drugs 363 , 370 334, 600 604* 605
lithium 358, 387, 390, 391 396-398 356, 395,
606-611
PCPA 37, 350* 399* 483, 612, 613
485, 490, 491, 500,
591, 592
morphine 127, 540, 541, 593- 545-547, 549, 550-553, 614
596 601, 602
barbiturate 554, 567, 598 547, 568, 603 569, 570
The influences of catecholamines and their precursors on 5HT metabolism
have been mentioned already (see Discussion 3.4.4). It is possible, therefore,
that changes in the nucleolar dry mass of raphe or suprachiasmatic neurones
which were observed in the present study were the indirect result of altered
metabolism in central noradrenergic neurones, rather than the direct result
of the deranged metabolism of raphe neurones. However, the intraperitoneal
injections of oxypertine and phenylalanine, and the intraventricular admini¬
stration of noradrenaline and 6-hydroxydopamine failed to alter the nucleolar
dry mass of raphe neurones (see Results 3.3 and 3.4.3). This finding may
indicate that the production of ribosomes for protein synthesis in raphe
neurones is not affected significantly by drug-induced changes in the release
of noradrenaline by noradrenergic neurones in brain.
Thirdly, the significance of the nucleolar dry mass changes in raphe
neurones requires discussion. Changes in this parameter accompany altered
metabolic demands for the ribosomal synthesis of proteins and enzymes involved
in various cellular activities (see Introduction 1.1). Stimuli including drugs
might be expected to alter many facets of neuronal activity. After axonal or
terminal damage, for instance, cellular activities such as dendritic restruc¬
turing (315-318) and axonal sprouting take place, accompanying that
accelerated synthesis of ribonucleic acid and protein which is associated
with neuronal repair and regrowth (148, 179, 221, 618-622). Nevertheless,
it may be justifiable to interpret more narrowly the nucleolar dry mass
responses of neurones to specific stimuli which alter the functional activity
of these cells (20, 21, 106); included in the functional activity of neurones
are processes such as the synthesis, transport, storage, release, reuptake
and catabolism of the relevant neurosecretion or neurotransmitter (109).
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In raphe neurones, the nucleolar changes may reflect drug-induced
alterations in the metabolic requirements for one or more of the following
enzymes: (a) those responsible for synthesizing 5HT, in particular the
rate-limiting enzyme tryptophan hydroxylase (see Introduction 1.2.3),
(b) those responsible for synthesizing the storage vesicles for SHT,
(c) those responsible for the catabcllsm of excessive amounts of intra-
neuronal 5HT, especially MAO, and (d) those associated with processes
accompanying the electrical activity of the neurones, including the discharge
and recharge of amine-storage vesicles (623) (see Fig. 4.1.).
There is no obvious relationship between the nucleolar changes
observed in raphe neurones after various drug regimes and the effect of
these drugs on synaptic vesicles (Fig. 4.1.). Reserpine is a drug whose
actions include damage to storage vesicles (see Introduction 3.1.1 and
Discussion 3.1.4); it could be argued therefore that the increase in nucleolar
dry mass after reserpine alone (Results 3.1.3) reflected predominantly the
increased cellular production of rlbosomes necessary for the accelerated
synthesis of proteins and other components of vesicles (178, 179, 317).
But this argument is difficult to sustain when considering the reserpine-
nialamide and reserpine-desfpramine studies, in which no nucleolar changes
were observed despite the action of reserpine. Moreover, nucleolar changes
similar to those produced by reserpine alone were elicited by drugs such as
lithium and testosterone, which do not damage vesicles, so far as is known.
Hence in these experiments, additional synthesis of vesicular proteins
probably could not account for the changes in nucleolar dry mass of raphe
neurones.
Equally difficult to discern is a relationship between nucleolar
changes in raphe neurones and putative alterations in MAO activity. It
might be argued that in the lithium and reserpine experiments, the enhanced
MAO activity associated with the elevated 5HIAA content of brain could be
connected with the increased nucleolar dry mass of the raphe neurones.
But after nialamide and tranylcypromine alone there were no nucleolar
changes despite the concurrent inhibition of MAO. Moreover the admini¬
stration of tryptophan and 5HT, which reportedly increases brain 5HIAA
(see Introduction 1.2.3 and Discussion 3.4.4) was accompanied in the
present investigation by unchanged or decreased values for nucleolar dry
mass. The only detectable action of MAO inhibitors on this raphe neuronal
parameter was the abolition of the increased dry mass caused by reserpine
(see Results 3.2.3) - and possibly by PCPA (see Results 3.4.3); it has
been shown elsewhere that in the presence of MAO inhibition, the trans-
synaptic induction o£ enzymes in noradrenergic neurones is blocked (321).
The rate of 5HT synthesis in the raphe neurones has been related to
their impulse activity (201) (see Introduction 1.2.6). In some studies,
drug-induced changes in the firing-rate of raphe neurones are considered
indices of short-term alterations of their metabolic activity (155). For
example, it is reported that after the administration of tryptophan, reser¬
pine, imipramine-like drugs or MAO inhibitors, the rate of firing decreases;
and that after PCPA pretreatment, the inhibition of firing caused by MAO
inhibitors and by imipramine-like drugs is absent (344, 360, 377). These
changes in firing rate have been considered to stem from the activation
of post-synaptic 5HT receptors (264), with consequent feedback inhibition
of raphe neuronal function (see below). But there are discrepancies between
these electrophysiological changes, the reported changes in 5HT synthesis,
and the alterations in the nucleolar dry mass of raphe neurones in the
present investigations (Fig. 4.1.). After drugs such as lithium and reser-
pine, the rate of 5HT synthesis rises and the nucleolar dry mass increases;
yet after lithium, the firing rate of raphe neurones does not increase (270),
while after reserpine (given intravenously) their firing rate increases
within 20 minutes, is inhibited between 18 and 24 hours after the injection,
and then returns to normal values (377). Again, after MAO inhibition,
the firing-rate of raphe neurones declines rapidly; yet in the present
study, the nucleolar dry mass of raphe neurones was unaltered (Results
3.2.3). According to some reports, the rate of 5HT synthesis does not
alter after MAO inhibition (200, 506) (Discussion 3.2.4). Moreover in
those studies where a decreased tryptophan hydroxylase activity has
been reported after MAO inhibition (Discussion 3.2.4), change may have
resulted from altered activity of extant enzymes (43, 155) - perhaps by
end-product inhibition - rather than by trans-synaptically induced changes
in the rate of tryptophan hydroxylase biosynthesis (01, 259, 624). A
similar dual control over the rate of noradrenaline formation by tyrosine
hydroxylase has been proposed (109, 623, 625-627) (see Introduction 1.2.9).
Other observations on 5HT turnover and histofluorescence in the segments
of the transected spinal cord indicate that, after MA J inhibition, 5HT
synthesis is probably not controlled by mechanisms such as end-product
or feed-back inhibition (200). It may be that, during MAO inhibition, the
raised concentration of "free" intraneuronal 5HT inhibits raphe neuronal
firing directly, through effects on the transmembrane potential of raphe
neuronal terminal£(86, 499), rather than through mechanisms in their cell
bodies. For after MAO inhibition,, there are no morphological changes in
the Qolgi apparatus of raphe neurones such as have been found when cellular
biosynthetic activity is altered (128, 180).
Hence the discrepancies between changes in electrical activity in
raphe neurones and alterations in their synthetic activity or nucleolar dry
mass after drugs support the hypothesis described earlier (see Introduction
1.2.9): fluctuations of impulse activity may be linked only to short-term
alterations in the rate of 5HT synthesis; these transient alterations in
synthesis-rates can result from changes in the degree of enzyme activation,
rather than from an altered rate of biosynthesis of new enzyme (24, 146, 155,
201, 241, 624, 627, S28). These discrepancies also support the v4.?w tb?fc
changes in the nucleolar dry mass (and the accompanying alterations in ribosome
synthesis) are not closely associated with those metabolic processes involved
in raphe neuronal impulse activity. Other workers, too, have indicated
that changes in the turnover of 5HT in raphe neurones and alterations in their
electrical activity are not necessarily concomitants (201, 481, 628).
The outstanding biosynthetic relationship requiring scrutiny is that
between changes in the nucleolar metabolism of raphe neurones and the
altered requirements for enzymes necessary for 5HT synthesis, in particular
tryptophan hydroxylase. Within monoamine neurones, the ainines may be
present in different subcellular compartments or pools with different rates
of synthesis and destruction of the amine (259, 265, 629). Because the
amines in these pools may be interchangeable over a period of time (259,
323, 475, 522, 630, 631), these intraneuronal pools have been considered
as a functional entity (632, 633). In addition there exists an extraneuronal
pool of 5HT (481): the 5HT molecules in this pool enter it when they are
released from raphe neuronal terminals as a result of nervous activity
(Introduction 1.2.6). Having entered the synaptic gap, the extraneuronal
5HT may combine with receptors on postsynaptic cell membranes; but
provided the membrane pump of the raphe terminals is intact, this extra¬
neuronal 5HT is then pumped back into the intraneuronal pool of 5HT.
The size of this extraneuronal pool can vary. It can be altered directly
by drugs such as the tricyclic antidepressants, or by the intraventricular
infusion of 5HT and melatonin (Discussion 3.4.4); or it can be altered
indirectly by substances such as reserpine or (perhaps) tryptophan which
change the amount of intraneuronal 5HT available for release (478, 634)
(Discussions 3.1.4 and 3.4.4). Correlations can be sought between the
nucleolar responses of raphe neurones and the status of these intraneuronal
and extraneuronal pools of 5HT after various procedures (Fig. 4.1.).
No relationship was discernible between the nucleolar dry mass of
the raphe neurones and the probable size of the intraneuronal pool of
5HT during these investigations (Fig. 4.1.).
An inverse relationship is apparent between the amount of 5HT (or
of the closely-related molecule, melatonin) probably present in the extra-
neuronal pool, and the nucleolar parameter of the raphe neurones. This
inverse relationship is compatible with the concept of feedback control of
raphe neurones, which has been proposed by many workers (222, 264, 266,
267, 327, 377, 427, 635-639). According to this concept, when receptors
on neurones innervated by raphe neuronal terminals are exposed to an
increased amount of 5HT released from these terminals, they activate a
feed-back loop. Perhaps by means of a diminished trans-synaptic input,
-/
this loop inhibits the metabolic activity of raphe neurones, and in particular
the synthesis and release of 5HT; the biosynthesis of tryptophan hydroxylase
in the raphe neurones may also be Inhibited, if the pattern of control of 5HT
neuronal metabolism is similar to that of noradrenergic neurons 3 (107, 623,
640) (see Introduction 1.2.9).
However, in some experiments in this study, this inverse relationship
was abolished by procedures which probably grossly increased the amount
of 5HT in the synaptic pool (Methods 3.3.2 and 3.4.2). Although there is no
direct evidence to support the conjecture, it may be that such paradoxical
findings reflect the development of receptor hyposensitivity or tachyphylaxis
(see Introduction 1.2.7 and Discussion 3.3.4). For the reasons stated
earlier (see Discussions 3.1.4 and 3.4.4( Concluding Discussion 4.1) it is
less likely that these findings resulted from the disordered function of nor¬
adrenergic neurones. However the contribution erf these neurones and
also of different control mechanisms (624, 641-644) to the regulation of
5HT metabolism in raphe neurones remains unclear.
The changes in nucleolar dry mass of the different hypothalamic
neurones examined require cautious interpretation. These neurones have
a variable quality and quantity of monoaminergic afferent input. Moreover
they are not known to synthesize specific, identifiable and measurable neuro¬
transmitters, the turnover of which would illustrate their metabolic activity.
Therefore it is difficult to elucidate how the various drugs in the present
study may have affected the metabolism erf these neurones.
The inhibitory action of 5HT on neuronal firing has been demonstrated
in the suprachiasmatic nucleus (see Introduction 1.2.7). The decreased
nucleolar dry mass of the suprachiasmatic neurones after lmipramine, or
their increased nucleolar parameter after reserpine (see Results 3.1.3,
3.3.3) may flow indirectly from changes in the 5HT concentration in the
synaptic spaces within this nucleus.
During the period when the experiments in this thesis were being
performed, the baseline values for the mean nucleolar dry mass of various
neurones were sometimes found to fluctuate between batches of rats, but
not within batches. Similar fluctuations in this nucleolar parameter of
other groups of neurones have been reported (20, 21). In rats and mice,
the metabolism of 5HT by raphe neurones may vary between different
strains of these a imals (124, 645, 646). In the present study, a seasonal
cause for the fluctuations in nucleolar dry mass of the raphe neurones could
be excluded; but it was not possible to investigate furtner the genesis of
these fluctuations.
Some of the findings reported in the present study require to be
amplified by further experimentation, designed to investigate the duration of
drug-induced nucleolar changes, their dose-response relationships, and
the effects of drug-withdrawal.
The effect of hallucinogenic substances on the nucleolar dry mass of
raphe and suprachiasmatic neurones requires to be investigated: many of
the hallucinogens, in particular mescaline and lysergic acid (264, 647-650)
have been shown to alter other facets of 5HT metabolism in brain.
The suggested involvement of 5HT metabolism in thermoregulation
(232, 651-653) and in the control of sex hormone activity (232, 09, 654,
655) is intriguang. In the former field, the raphe neuronal response to
extremes of environmental temperature and to the manipulation of thyroid
function could be observed. As for the latter field, the stages of physiological
interest include pregnancy (656), lactation (657) and the neonatal period (658,
659).
It would be of interest to see whether or not the hypothesis established
in this thesis, concerning the control of ribosome synthesis in raphe neurones,
could be further supported by such investigations.
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4,2 Summary
The nucleolar dry mass of interneurones in the brainstem and
hypothalamus of the i*at was measured by interference microscopy. The
values for nucleolar dry mass in some neurones changed when the experi¬
mental animals were subjected to various procedures. The raphe neuronal
parameter increased after the administration of reserpine. lithium, diamor-
phine and testosterone; it decreased after imipramine and desipramine, and
after 5HT. melatonin and barbitone. The suprachiasmatic neuronal para¬
meter increased after reserpine and diamorphine. but decreased after
imipramiue and desipramine. barbitone and testosterone. The arcuate
neuronal parameter declined only after barbitone. The ventromedial
neuronal parameter decreased after reserpine. No changes in the
nucleolar dry mass of the supraoptic, dorsomedial and posterior neurones
of the hypothalamus were observed.
APPENDICES
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APPENDIX I. INTERFERENCE MICROSCOPY: derivation of formulae
-r i i.i - - - l l i l i i ii -k
Full accounts of the principles of interference microscopy, and the
use of this technique to measure nucleolar dry mass of neurones are
available (20, 21, 662-605).
As described earlier in the text (see General Methods 2.4.2) two
coherent beams of light emanate from the light source in an interference
microscope. If a translucent organelle is placed in the path of one of
these beams, the degree of retardation (Dw) or optical path difference (OPD)
between the beams, is determined by the relationship.
where No = refractive index erf the organelle,
Nw « refractive index of water
t = thickness of organelle
The refractive index of the organelle consisting of an aqueous solution
is related to the solute concentration and to the specific refractive increment
of the solution:
x _ No-Nw where C = concentration, g/ml.
Dw « (No-Nw)t (1)
C
X » 100.x, and
x » specific refractive incre-
No-Nw
when x - ■ ■■ ■ • ment, or the increase in
therefore No » X, C + Nw
refractive index per increase
(3)
in solute concentration in
g/lOOml
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Suppose an organelle be represented as a disc of homogeneous solution,
which is immersed in water,
M
then C -— (4) when M = mass of solute in g.At
2
A * area in cm .
t = thickness of disc in cm.
Substituting for C in equation (3)
M No-Nw
At * X
andM , (No-Nw)A. t (#)
A
But in equation (1), (No-Nw)t = Dw
therefore M = (6)
A
that is, OPD is proportional to Mass per unit area. The value for dry
mass can be calculated if the quantities Dw, area, and X are measurable.
The organelle as a nucleolus
2
The volume of this disc-shaped organelle - ifr h
where r = disc radius
h » disc height.
A nucleolus can be considerc ; as a sphere (20) with a volume equal to
that of the organelle,
4 3 2
then nucleolar volume 3 - fr" a 1fr h
O
4
and height of disc, h « rr = 2/3d, where d » diameter in cm.3
The OPD imposed on a light beam perpendicular to this disc of height 2/3d
will be uniform in this axis.
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Hence for the nucleolar sphere, whose diameter = d, tne mean thickness
or height along which OPD will be uniform » 2/3d.
Since Dw « (No-Nw)t (1)
then D mean = (Nn-Nw)2/3d
and D peak = (Nn-Nw)d, or (Nn-Nw)= ' -^a'c
2
By substitution, Dmean = —Dpeak (7)
u
The nucleolus in media other than water
Nucleolar dry mass can be measured accurately only when its maximal
imposed OFD is less than 0.2L, where L = wavelength of light used.
To ensure this situation, the nucleolus in its nucleus is placed in a medium
with a refractive index greater than that of water. In this medium, the
OPD, or Dm - (No-Nm)d (8)
hence from equation (6),
Dm.A. No-Nw
M-
X No-Nm 8 <9>
The nucleolus within the nucleus
An intranuclear nucleolus is enveloped by a layer of nucleoplasm of
refractive index (nN) which will contribute to the OPD measured over the
nucleolus. The mean thickness of these layers of nucleoplasm <p. (d-t)cm,
where d = mean nuclear thickness,
t = mean nucleolar thickness.
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When DN = mean OPD for perinucleolar nucleoplasm,
DN&O = mean OPD for this nucleoplasm plus nucleolus
Do = corrected mean OPD for nucleolus alone,
then DN^O « Do + DnJ-~-J = Do + DN'l-t/d),
therefore Do = DN&O - DN(l-t/d).
From equation (1), the OPD created by this nucleoplasm can be represented
as DN = (u~i.)(tus~lLn) (10)
By equation (8), the OPD due to the nucleolus alone is:
Dm - (No-Nm)d,
therefore the summed OFD due to nucleoplasm and nucleolus is:
Dm = (U-t)(nN-nM) + (No-Nm)d, = (nN-nM)(l-t/d) + (No-Nm)d (11)
From equation (10),
the OPD due to nucleolus alone,
(No-Nm)d = Dm-DN(l-t/a),
so from equation (9),
a f No-Nw
true nucleolar dry mass, M = - Dm-Dn(l-t/d) g (12)
The factors in this equation will now be considered in turn:
2
1) A: area in cm of the nucleolus normal to optical axis, can be
calculated using the value for d, as measured by mlcrodensitometry.
2) X: is approximately 0.18 for proteinaceous solutions, over a wide range
of concentration; this value is not significantly affected by alterations of
pH or temperature (862, 666). For DNA and BNA, values for X are quoted
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as 0,187, and 0.168 to 0.194 respectively. For glycogen, X is around
0.15 (667), Since nucleoli are overwhelmingly proteinaceous (1, 303 , 305),
the value, X = 0.18 is used in calculations of nucleolar dry mass (21, 306).
3) DN(l-t/d); the contribution of the nucleus to the measured OPD is
negligible, - about 1% (20); this lias been ascertained by measuring the
OPD of nucleoli firstly enclosed within nuclei, and then isolated, after
their extru^i_n from the nuclear envelope.
4) No-Nw ; of these refractive indices, Nm was measured by refracto-
No-Nra
metry and found to be 1.349; Nw is 1,333; from equation (6),
No = ~p+ Nm, and Table 2,4,5. shows the value No calculated for 50
randomly selected neurones from each nucleus.
Calculation of nucleolar dry mass from microdensltometrlc trace
Dm.A No-Nw
According to equation (9), M = , ——— g.A MO-JNDOi
On a densitometer trace (Fig, 2.4,4,), it can be seen that
a - distance in cm, from the nucleolar peak to the point of corres-
^ ' i' , £*->v ' i v.e-thH i
ponding intensity on the interference band;
La= distance in cm, between points of corresponding intensity on
adjacent interference bands;
a/La ■ peak nucleolar OPD as a fraction of 1 wavelength of light
used, L - 546nm;
d =■ diameter of nucleolus;
thus nucleolar M
2. L. a No-Nw . ir(d/212
3 X La No-Nm (Mag)2
3
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Effects of Diamorphine on Various Neurones in the Rat Central Nervous
System
Neurones of the raphe nucleus send axons to other regions
of the central nervous system, especially the hypothalamus.
These neurones synthesize serotonin, much of which is stored
in cytoplasmic vesicles, where it is protected from the action
of monoamine oxidase1. Accumulations of these vesicles are
found within varicosities at the raphe nerve terminals2. Reser-
pine causes the vesicles to release their serotonin contents;
once freed and thereby exposed to monoamine oxidase,
serotonin is broken down3. Whether or not serotonin
metabolism is affected by morphine and its derivatives has
remained a controversial topic4.
Interference microscopy has been used to demonstrate
quantitative metabolic changes in neurones with motor or
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Fig. 1 Raphe and suprachiasmatic neurones. Columns indicate
pooled mean nucleolar dry mass measurements with their stan¬
dard errors, grouped into controls and according to days after
starting diamorphine.
related to the intensity of the preceding stimulus5-7. This
technique was used to investigate three questions: first, do
cells which are interneurones rather than effector neurones
show similar metabolic changes; second, do interneurones
specifically involved in serotonin metabolism within the
central nervous system (CNS) (that is the raphe and supra¬
chiasmatic neurones) show metabolic changes after diamor¬
phine; third, are such changes comparable with the same
neurones' responses to reserpine?
Changes in neurones from the median raphe region of the
midbrain were compared with the responses of the hypothalamic
suprachiasmatic neurones, which are enmeshed in large
numbers of terminals containing serotonin. In addition the
responses to the same stimuli were investigated in neurones
from regions of the hypothalamus where serotonin terminals
are scanty and where catecholamine terminals predominate,
for example, ventro-medial, dorso-medial, posterior, pre-optic,
anterior and posterior arcuate regions.
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Control 9.37 ±0.39
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Drugs and control solutions were given by intraperitoneal
injections to male albino rats (aged 3 months and weighing
about 250 g). These were killed by exsanguination after light
ether anaesthesia. Small blocks of tissue (0.5 mm x 1 mm)
containing the relevant neurone groups8 were excised from
slices of midbrain and hypothalamus. Specimens of isolated
neuronal nuclei were prepared, and the dry mass of their
nucleoli was measured by interference microscopy5. Group A
consisted of rats given diamorphine (1 mg twice daily) for up
to 20 d (Figs 1 and 2). Group B rats received reserpine
(0.5 mg daily) for up to 10 d, after which the drug was with¬
drawn (Figs 3 and 4). Group C rats were given reserpine
(1 mg daily) for up to 9 d (Fig. 5). In all experiments control
animals received appropriate volumes of Ringer lactate
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Fig. 3 Raphe and suprachiasmatic neurones. Columns indicate
pooled mean nucleolar dry mass measurements with their
standard errors, grouped into controls and according to days
after starting reserpine and subsequently withdrawing the drug.
during the experiments, and the dry mass response of the
neuronal nucleoli from the different regions was observed.
From the figures and from the statistics shown in Table 1,
the following points are evident: (1) Interneurones behaved
like effector neurones in showing nucleolar metabolic changes
after specific stimulation. (2) Diamorphine selectively increased
the metabolism of these neurones involved in serotonin
metabolism; the median raphe response preceded by some
[f| rfi rfi ft f
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Posterior Days Preoptic Ventro-medial
Fig. 4 Various other neurones. Columns illustrate data as
in Fig. 3.
days a similar response in the suprachiasmatic neurones (Fig. 1).
(3) When the rats were given the low dose of reserpine, the
raphe and suprachiasmatic neurones again demonstrated
similarly sequential, but earlier, increases in cell metabolism;
on withdrawing the drug the parameters in both regions
returned to normal over a few days, the decline in the raphe
parameter showing the earlier onset (Fig. 3). (4) The meta¬
bolic responses of these two regions differed further in that
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Fig. 5 Raphe and suprachiasmatic neurones. Columns
indicate pooled mean nucleolar dry mass measurements with
their standard errors, grouped into controls and according to
days after starting reserpine (high dose).
inhibited that of the suprachiasmatic neurones (Fig. 5).
(6) Those neurones not directly implicated in serotonin meta¬
bolism did not respond to diamorphine (Fig. 2); with the
exception of the unexplained ventro-medial neurones' response
to the low dose of reserpine, this drug also had no effect on
those neurones (Fig. 4), a conclusion supported by data
showing their unresponsiveness to high doses of reserpine
(unpublished observations).
An increased cell nucleolar dry mass is associated with
heightened nucleolar synthetic activity5,7. Neuronal nucleolar
volumes are also correlated with cell RNA levels9; these, in
turn, are linked to changes in rates of protein synthesis10. In
this study, in which nucleolar dry mass varied directly with
nucleolar volume (unpublished observations), the raised raphe
parameters noted during chronic diamorphine and reserpine
administration may indicate accelerated synthesis of enzymes
concerned in the formation of serotonin and possibly of its
storage vesicles. The time lag between the raphe and supra¬
chiasmatic responses to diamorphine and reserpine may repre¬
sent the time needed for the products of the increased raphe
metabolism to reach the terminals around the suprachiasmatic
neurones.
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Inhibition of median raphe neurone metabolism by cerebrospinal fluid (CSF) containing
5-hydroxytrvptamine and melatonin
(Received 25 September 1973; accepted 24 November 1973)
Brain 5-hydroxytryptamine is synthesized by many neurones of the raphe nucleus in the midbrain. For
several hours after monoamine oxidase inhibition the rate of 5-hydroxytryptamine synthesis declines
as the level of brain 5-hydroxytryptamine rises.1,2 In the present study the nucleolar component of the
metabolic changes in median raphe neurones was observed (a) during a prolonged (9 day) elevation
of 5-hydroxytryptamine levels in cerebrospinal fluid (CSF), (b) during a similar elevation in CSF levels
of other monoamines, (c) after depletion of brain catecholamines by 6-hydroxydopamine (6-OHDA),3
and (d) after bilateral cervical sympathectomy.
The cerebral ventricles of one group of male albino rats (aged 3 months and weighing approximately
300 g) were cannulated and continuously infused during 7-9 days, at a rate (1 /tl/min) roughly half that of
CSF formation.4 The infusate was artificial CSF alone, or with "low-dose" 5-hydroxytryptamine,
melatonin, noradrenaline, histamine (all at 50 jUg/ml), tryptophan (1 mg/ml), or "high-dose" 5-hydroxy¬
tryptamine (500 tig/ml). The rats were killed after 7-9 days of infusion.
In a second group of rats, 6-OHDA (250 pg in 0-05 ml artificial CSF) was given by a single injection
into a lateral cerebral ventricle; controls received artificial CSF alone. The animals were killed at intervals
during the following 16 days.
In a third group, bilateral cervical sympathectomy was performed and the rats killed 7-9 days thereafter.
From all rats, neuronal nuclei were isolated from the median raphe region of the brain.5 The dry mass
of the nucleoli in these nuclei was measured using the interference microscope,6 and the mean values are
shown in Fig. 1 and Table 1.
Although the drug-induced behaviour of the rats within each group was similar, differences between
the groups were seen. Two days after commencing infusion with melatonin or with "low-dose" 5-hydro¬
xytryptamine the rats became very drowsy and showed a reduction both in spontaneous motor activity
and in reactivity to simple tactile and auditory stimuli. During infusion with "high-dose" serotonin the
rats were drowsy in the first day only, subsequently becoming hyperactive and hyperreactive with a coarse
tremor and titubation. Rats with noradrenaline or tryptophan in the infusate showed increased spon¬
taneous movements and hyperreactivity starting on day 2 but not preceded by drowsiness. For 1 hr after
6-OHDA injection the rats were hyperactive and hyperreactive; the subsequent 12-hr phase of extreme
immobility and unresponsiveness disappeared gradually, behavioural normality returning during day 2.
Those rats with cervical sympathectomy and those receiving histamine solution or artificial CSF by itself
appeared normal. Assiduous attempts have been made by many workers to attribute such drug-induced
changes in behaviour to concurrent changes in brain biochemistry.7,8 It is hoped that such speculations
might be assisted by this study in which accompanying changes in neuronal metabolism have been noted
by means of a different technique.
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Fig. 1. Raphe neurones: columns indicate pooled mean nucleolar dry mass measurements with their stan¬
dard errors, grouped according to experimental procedure.
A cell's metabolic capacity for synthesizing protein depends largely on its complement of ribosomal
RNA. The varying rate of ribosomal RNA synthesis necessary in changing circumstances can be related
quantitatively to alterations in the cell's nucleolar dry mass.6,9'10 Thus from the measurements of the nuc¬
leolar dry mass of raphe neurones in this study (Fig. 1, Table 1) the following deductions can be drawn:
(1) raphe neurone metabolism is depressed by the prolonged infusion of 5-hydroxytryptamine ("low-dose")
and of melatonin, two hormones which are biochemically closely related; (2) the raphe neuronal inhibition
produced during melatonin infusion is unlikely to be secondary to changes in pineal metabolism; for
although the amount of melatonin synthesized by the pineal gland is altered by bilateral cervical sypathec-
tomy," in this study the same procedure does not alter the raphe parameter; (3) the inhibition induced
during 5-hydroxytryptamine and melatonin infusion is not mediated by changes in the metabolism of
neurones synthesizing other monoamines; this is indicated by the stability of the raphe parameter during
the noradrenaline, 6-OHDA and histamine experiments; (4) the similar stability in the raphe parameter
during tryptophan infusion demonstrates that an increased availability of precursor does not alter the
nucleolar metabolism of raphe neurones; (5) "high-dose" 5-hydroxytryptamine infusion abolishes the
inverse relationship noted here and elsewhere1,2 between the rate of raphe neurone metabolism and brain
levels of 5-hydroxytryptamine.
Table 1.
Nucleolar dry No. of observations
Procedure mass (g x 10"12) and animals P values
Infusion control 817 ± 0-29 205; 4
5-Hydroxytryptamine (low dose)7-12 + 0-24 333; 6 0-01-0-005
Melatonin 6-98 ± 0-20 358; 5 <0-001
Tryptophan 8-23 + 0-33 257; 5 N.S.
Noradrenaline 8-28 + 0-45 104; 2 N.S.
Histamine 8-02 + 0-29 237; 3 N.S.
5-Hydroxytryptamine(high dose)8-24 ± 0-25 328; 4 N.S.
Sympathectomy 7-96 ± 0-25 262; 3 N.S.
6-OHDA Control 8-55 + 0-30 198; 3
6-OHDA dl-4 8-40 + 0-22 268; 4 N.S.
d5-7 8-22 ± 0-28 187; 3 N.S.
dl1-16 7-95 + 016 535; 7 (0T-0-05)N.S.
N.S.—not significant.
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It is not certain what physiological mechanisms decrease the tempo of 5-hydroxytryptamine production
in raphe neurones when the level of brain 5-hydroxytryptamine rises. The findings in this study support
the hypothesis12,13 that receptors relatively specific for 5-hydroxytryptamine are situated distal to raphe
nerve endings; these receptors' neurones control, by feedback inhibition, an excessive rate of 5-hydroxy¬
tryptamine production by the raphe neurones as evidenced by moderately raised levels of 5-hydroxytryp¬
tamine at the receptors. This study further suggests that, at very high levels of 5-hydroxytryptamine, these
receptors become saturated and inactivated; in this situation the inhibitory feedback control is eliminated.
Experiments now in progress are designed to test the validity of this hypothesis.
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Species differences in lipid peroxidation and their effects on ethyl-
morphine .Y-dernethylase activity in liver microsomes
(Received 5 July 1973; accepted 2 November 1973)
We have recently demonstrated the close inverse relationship between lipid peroxidation and activities
of drug-metabolizing enzymes in liver microsomes of rats.1 Regarding the changes in ethylmorphine N-
demethylating activity, the activity was decreased when microsomes were incubated in the presence of
ferrous ion. and was apparently increased by incubation of microsomes with inhibitors of lipid peroxida¬
tion such as EDTA, o-phenanthroline, <x,oc'-dipyridyl and Co2'. The present study was initiated in order
to examine further the effects of EDTA and ferrous ion on lipid peroxidation and activity of ethylmor¬
phine N-demethylase in liver microsomes from various species.
Thiobarbituric acid (TBA) and ethylmorphine were purchased from commercial sources and used with¬
out further purification. Thiobarbituric acid solution (0-67%) was prepared as previously described.'
NADP, glucose 6-phosphate-Na and glucose 6-phosphate dehydrogenase (EC 1.1.1.49, grade I, Kontroll-
Nr. 7291111) were purchased from Boehringer Mannheim (Japan) Co. Ltd.
Male rats (Sprague-Dawley strain) weighing 70-90 g, male mice of dd strain weighing 23-27-5 g, male
guinea pigs weighing 320-340 g, and male albino rabbits weighing 2-25—2-61 kg were maintained on com¬
mercial chow, and were starved for about 18 hr prior to sacrifice. Three livers of rats and 12 livers of mice
were pooled and used for each respective experiment. Liver microsomes of the animals were prepared
by a method previously described.1
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